US20070021803A1 - Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction - Google Patents
Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction Download PDFInfo
- Publication number
- US20070021803A1 US20070021803A1 US11/459,582 US45958206A US2007021803A1 US 20070021803 A1 US20070021803 A1 US 20070021803A1 US 45958206 A US45958206 A US 45958206A US 2007021803 A1 US2007021803 A1 US 2007021803A1
- Authority
- US
- United States
- Prior art keywords
- energy
- nerve
- catheter
- pain
- poration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0412—Specially adapted for transcutaneous electroporation, e.g. including drug reservoirs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B18/1477—Needle-like probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0456—Specially adapted for transcutaneous electrical nerve stimulation [TENS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0472—Structure-related aspects
- A61N1/0492—Patch electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0551—Spinal or peripheral nerve electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/36021—External stimulators, e.g. with patch electrodes for treatment of pain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36071—Pain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/36017—External stimulators, e.g. with patch electrodes with leads or electrodes penetrating the skin
Definitions
- the present invention relates to methods and apparatus for the treatment of nerve function, and more particularly, for selective disruption of conduction pathways in the body for the treatment of pain and other disorders associated with nerve conduction in various regions within the body.
- Irreversible surgical ablation has been relied upon for the treatment of chronic pain. Lesions are placed on or in the peripheral nerves, spinal chord or brain, but such placement can have side effects such as unintended motor system effects, and required open, surgical procedures. More recently, reversible electrical and localized pharmacologic solutions started to be used.
- TENS Transcutaneous Electrical Nerve Stimulation
- non-invasive (skin surface) electrical stimulation to the large mylenated fiber spinal afferents, which functionally blocks nerve signal transmission to essentially create a “short circuit” between the nerve fibers and the sensory pathway to the brain.
- TENS may be applied to peripheral nerve stimulation, as well as spinal chord stimulation utilizing electrodes placed at the site of the targeted nerve.
- Electroacupuncture or Acupuncture Like Transcutaneous Nerve Stimulation has been employed with the goal of optimizing the release of endorphins and serotonin to combat pain.
- Various electrical stimulation devices are described in U.S. Pat. Nos. 4,573,481, 3,911,930 and 4,141,365, each of which is hereby incorporated by reference in their entirety.
- LISS Cranial Stimulator and the LISS Body Stimulator (LBS) which deliver a monopolar current at a frequency of 15,000 Hz, modulated at 50 ms “on” and 16.7 ms “off” has been used for pain treatment.
- LCS LISS Cranial Stimulator
- LBS LISS Body Stimulator
- Stimulation of the sensory thalamus and periaqueductal or periventricular gray in the deep brain has also shown promise in treating patients that have not been helped by other less invasive modalities of treatment.
- electrodes are placed in the targeted regions of the brain under stereotactic guidance. Stimulation is then applied and when a satisfactory results is achieved, a signal generator may be implanted for long term use.
- a variety of severe side effects can result from this approach however, including intracerebral hemorrhage and life threatening infections.
- opiates and narcotics Another approach used widely is orally administered opiates and narcotics, however the systemic effect and addictive nature of the oral medications make them less likely to provide a long term solution.
- Localized drug delivery or intraspinal drug administration has also shown promise, due to the fact that the approach requires significantly lower doses of narcotics that are delivered directly to the targeted region of the spinal chord either through epidural or intrathecal administration.
- percutanoues catheters may be placed at the target region, and attached to implantable (subcutaneous) reservoirs or pumps, or external drug pumps. Even though the narcotics are localized, side effects may still present, including impairment of motor function, nausea, constipation, ulcers and other side effects attendant oral narcotic administration.
- Advanced Neuromodulation Systems manufactures an RF transmitter and probe for spinal chord stimulation as well as an implantable drug delivery system to relieve chronic pain, the latter being described in U.S. Pat. No. 5,938,690, hereby incorporated by reference in its entirety.
- Vertis Neuroscience provides externally placed, targeted electrode arrays that provide stimulation to the upper and lower back to provide relief to chronic pain referred to as Percutaneous Neuromodulation Therapy (PNTTM).
- PNTTM Percutaneous Neuromodulation Therapy
- Synaptic Corporation provides a product for external stimulation for chronic pain by creating electrical impulses along specific sensory nerve pathways to inhibit pain signals to the brain, effect tissue healing, and produce general tissue anesthesia, as further depicted in U.S. Pat. No. 6,161,044, hereby incorporated by reference in its entirety.
- US2004/0186532 describes an electrode implantable in the brain stem to deliver electrical stimulation to treat pain.
- Additional implantable systems include, a rechargeable spinal chord stimulation system that includes an implantable pulse generator and leads attached to various regions of the spine that are connected to an external remote control or alternative charging system.
- a rechargeable spinal chord stimulation system that includes an implantable pulse generator and leads attached to various regions of the spine that are connected to an external remote control or alternative charging system.
- Such systems are available from Advanced Bionics, a division of Boston Scientific, Natick, Mass. and from Medtronic, Inc. Minneapolis, Minn. Such systems are described in U.S. Pat. No. 6,847,849.
- the Medtronic system may also include drug delivery technology including intrathecal drug delivery.
- the methods and apparatus preferably are minimally invasive or non-invasive, are targeted to specific tissue, such as nerve tissue, and provide a long therapeutic effect. It would further be desirable to provide devices and methods that modify nerve function without necessarily causing permanent physical nerve damage (neuralgia) that can occur once the treated nerve regenerates. At least some of these objectives will be met by the inventions described below.
- the present invention provides methods and apparatus for treating pain and other nerve related disorders where the methods and apparatus are minimally or non-invasive, controlled and selective, and/or offer a more durable effect.
- Target nerves include nerves in the spine, particularly cervical, thoracic, lumbar and sacral regions of the spine; peripheral nerves; nerves of the head and neck; and the brain stem.
- the “poration” of the target nerve may be reversible or irreversible, as desired.
- Reversible electroporation may be used in conjunction with a nerve blocking agent, chemical or other therapeutic agent to enhance, modify or otherwise modulate disruption of the nerves and/or targeted tissue.
- methods and apparatus for treating chronic pain and other neural defects by delivering an electric, ultrasonic or other energy field generated by a pulse or pulses of a designated duration and amplitude to disrupt nerve or other tissue at the cellular level via permeabolization of the cell or cell membrane.
- the energy may be delivered under conditions selected to cause irreversible cell damage by the creation of pores in the cell membrane which result in the death of the cell.
- the conditions may be selected to cause reversible or partially reversible cell damage.
- intracellular electromanipulation of the targeted tissue using ultrashort electric field pulses leading to apoptosis of the targeted cell may be desirable.
- a further aspect of the invention is to provide methods and apparatus for treating chronic pain and other neural defects by utilizing an electric field to disrupt tissue at the cellular level via permeabolization of the cell causing reversible electroporation of the cellular membrane, preferably by delivering an electric pulse or chain of pulses having a voltage between 40V and 1,000,000V.
- a therapeutic agent such as a nerve blocking agent, a neurotoxin or neurotoxin fragment, such as the light chain portion of botulinim toxin serotype A.
- the target nerves are frequently located adjacent to arteries which can be used for percutaneous access to the nerves for example, vascular catheters having electrodes, ultrasonic transducers, or other energy sources at their distal ends may be advanced through an artery to an arterial site adjacent to the target nerve which often runs directly along the outside of the artery energy can be applied which denervates the nerve while leaving the arterial wall intact as the nerve cells are more susceptible to injury.
- vascular catheters having electrodes, ultrasonic transducers, or other energy sources at their distal ends may be advanced through an artery to an arterial site adjacent to the target nerve which often runs directly along the outside of the artery energy can be applied which denervates the nerve while leaving the arterial wall intact as the nerve cells are more susceptible to injury.
- a single treatment can damage the adjacent nerve for extended periods of months or more without damaging the artery used for access.
- arteries that can be used to access particular target nerves of the body regions include: Artery Nerve Carotid Cranio-facial Vertebral Cranio-facial Radial Peripheral (Arms and Hands) Femoral Lower limbs, Sciatica, Disc Pain Popliteal Lower limbs, Sciatica, Disc Pain
- patients suffering from refactory angina may be treated by reversible or irreversible disruption of the stellate ganglion in the neck in the area of the C6 vertebra ( FIG. 1B ) and/or of the paravertebral nerves in the spine in the area of the T6 vertebra ( FIG. 1B ).
- the stellate ganglion and associated nerves can be treated or denervated by passing a nerve poration catheter into the common, internal or external arteries, placing the treatment electrode(s) or other component adjacent the nerve level to be treated, and delivering energy to cause irreversible poration to the target nerves.
- Some nerves may be better accessed via catheter placement in the vertebral or subclavian arteries. Nerves in the area of T6 can be accessed by placing the treatment catheter in the aorta, anterior or posterior spinal arteries, radicular arteries, intercostal arteries, or medullary arteries.
- arteries accessed and nerves treated to address various pain syndromes should be considered exemplary in nature and not limiting. It should be recognized that any syndrome which is amenable by treatment by denervation will be amenable to treatment via by the inventive technology.
- FIG. 1A depicts a Dermatome showing areas of the body (skin) supplied by corresponding nerve fibers on front of body;
- FIG. 1B depicts a Dermatome showing areas of the body (skin) supplied by corresponding nerve fibers on rear of body;
- FIG. 2 depicts a side view of three vertebrae in a vertebral column showing certain relationships between spinal nerve roots and vertebrae;
- FIG. 3 depicts a schematic of spinal nerve and vertebrae.
- FIG. 4 depicts a generator and catheter system capable of supply pulsed electric fields to effect reversible or irreversible electroporation in targeted cells.
- FIG. 4A and 4 B depict catheter distal tips of the present invention in various configurations showing spaced apart electrodes, including an optional monitoring electrode.
- FIGS. 5 A-D depict various electrode catheter configurations adapted to deliver energy or energy and therapeutic agents to target tissue.
- FIG. 6 depicts a fully implantable pulse generator and lead of the present invention.
- FIG. 7 depicts an implantable receiver and external transmitter and controller for delivering energy according to the present invention.
- FIG. 8 depicts a schematic representing placement of the implantable version of the present invention.
- FIGS. 9A and B depict an electrode pad for placement on the skin of a patient, including one or multiple circuits, either smooth or incorporating microneedles.
- FIG. 10 depicts a method of use of the invention according to FIGS. 9A and 9B .
- FIG. 11 depicts a method of use of the invention according to FIG. 6 .
- FIG. 12 depicts a method of use of the invention according to FIGS. 5A-5D .
- FIG. 13 depicts a method of use of the invention according to FIG. 7 .
- FIG. 14 depicts a schematic of a nerve fiber showing the relative cell size allowing selective cell permeabolization of nerve cells.
- FIG. 15 depicts a schematic of a target nerve region being treated by a poration catheter in an adjacent artery.
- the present invention is directed to methods and apparatus for targeting, stimulating, and disrupting nerve tissue, or tissue adjacent nerve tissue (collectively “target tissue”) usually at the cellular level, in order to selectively denervate or disrupt nerves and nerve pathways responsible for creating a pain response in a mammalian body.
- Target tissue may be treated from one or more locations either adjacent to or at a distance from target tissue.
- the target tissue may include the nerve directly associated with the pain response and/or conduction pathways contributing directly or indirectly to the pain response.
- Pain syndromes that may be treated utilizing the present invention include, neuropathic and nociceptive pain, for example, musculoskeletal pain (back, neck shoulder), myofascial (muscle) pain, neuropathic pain (complex regional pain syndrome, central pain syndrome, neuralgia, neuropathy), headaches, cancer pain, fibromyalgia, pelvic pain, arachnoiditis, arthritis, facial pain (TMJ, Temporomandibular disorders (TMD)), sciatica, skin disorders (burn pain, shingles, herpes, tumors, vasculitis), spacicity, spinal chord injury or stenosis, sickle cell disease, and pain associated with vascular disease, both peripheral and cardiac.
- neuropathic and nociceptive pain for example, musculoskeletal pain (back, neck shoulder), myofascial (muscle) pain, neuropathic pain (complex regional pain syndrome, central pain syndrome, neuralgia, neuropathy), headaches, cancer pain, fibromyalgia,
- the body's nervous system consists of the central nervous system (brain), spinal chord nerves and the peripheral nervous system (sensory nerve fibers and motor nerve fibers outside of the brain and spinal chord).
- the system includes nerves (bundles of axons enclosed in connective tissue) and can be characterized as sensory/afferent, motor/efferent, or a combination of both sensory and motor fibers.
- the spinal nerves include fused nerve roots, for example, the dorsal root nerves are associated with sensory functions, and the ventral root nerves are associated with motor functions.
- Peripheral nerves may be cranial (arising from the brain), or spinal (arising from the spinal column), and are usually associated with sensations or motor functions in the hands, arms, legs or feet.
- Cranial nerves are mostly associated with motor function, or a combination of motor and sensory functions.
- the spinal nerves consist of 31 pairs of nerves organized into various regions along the spine the cervical (C), thoracic (T), lumbar (L), and sacral (S).
- the spinal nerves are further organized into nerve networks or nerve plexus including C1-C4 (cervical plexus), C5-C8 and T1 (brachial plexus), L1-14 (lumbar plexus), and L4-S4 (sacral plexus).
- the relationship between the spinal nerve and the muscle (myotome) and between spinal nerve and skin (dermatome) are depicted in FIGS.
- devices can target a relatively localized region of the spinal column depending on the type of pain or motor function and location of pain or motor function (dermatome or myotome) to be treated.
- Devices of the present invention may be directed to “targeted regions” such as cervical, thoracic, lumbar and sacral regions of the spine, peripheral nerves, nerves of the head and neck, brain stem, and deep brain.
- targeted regions such as cervical, thoracic, lumbar and sacral regions of the spine, peripheral nerves, nerves of the head and neck, brain stem, and deep brain.
- Some particular examples include, spinal chord modulation for chronic pain (for example application of energy of the present invention to the region of the spine at L1-L5 to treat lower limb and/or back pain), peripheral nerve modulation for chronic pain (for example the radial or ulnar nerve to treat hand or finger pain or dysesthesias.), and sacral nerve modulation to treat pelvic pain.
- the devices and methods of the present invention may also be employed to treat certain motor dysfunctions; for example, spinal chord nerve modulation to treat peripheral vascular disease (PVD), deep brain nerve modulation for tremor, Parkinsons, depression, obsessive compulsive disorder, motor dysfunction, and brain injury, and vagus nerve modulation for treatment of epilepsy, or obesity.
- PVD peripheral vascular disease
- Parkinsons depression
- obsessive compulsive disorder tremor
- motor dysfunction e.g., depression
- vagus nerve modulation for treatment of epilepsy, or obesity.
- the term “electroporation” can encompass the use of pulsed electric fields (PEFs), nanosecond pulsed electric fields (nsPEFs), ionophoreseis, electrophoresis, electropermeabilization, sonoporation and/or combinations thereof, permanent or temporary, reversible or irreversible, with or without the use of adjuctive agents, without necessitating the presence of a thermal effect.
- PEFs pulsed electric fields
- nsPEFs nanosecond pulsed electric fields
- ionophoreseis ionophoreseis
- electrophoresis electropermeabilization
- sonoporation and/or combinations thereof
- electrode used herein, encompasses the use of various types of energy producing devices, including antennas (microwave transmitters) and ultrasonic elements.
- antennas microwave transmitters
- ultrasonic elements include antennas (microwave transmitters) and ultrasonic elements.
- sonoporation cell membrane manipulation by application of ultrasonic energy, may have advantages in performing the therapeutic treatment of the present invention due to its ability to manipulate the membrane without producing as much heat at the treatment site as other energy modalities that have been used, and its ability to focus at a specific treatment site.
- the methods and apparatus of the present invention can employ reversible electroporationof the type used in medicine and biology to transfer chemicals, drugs, genes and other molecules into targeted cells for a variety of purposes such as electrochemotherapy, gene transfer, transdermal drug delivery, vaccines, and the like.
- Irreversible electroporation may also be employed as used for cell separation in debacterilization of water and food, stem cell enrichment and cancer cell purging (U.S. Pat. No.
- Ultrashort pulse lengths are directed at target subcellular structures without permanently disrupting the outer membrane.
- An example of this technology is described by Schoenbach et al. (2001) J. Bioelectromagnetics 22: 440-448, and in U.S. Pat. No. 6,326,177, the contents of which is expressly herein incorporated by reference.
- the short pulses target the intracellular apparatus, and although the cell membrane may exhibit an electroporative effect, such effect is reversible and does not lead to permanent membrane disruption.
- apoptosis is induced in the intracellular contents, affecting the cell's viability (for example limiting the ability to reproduce).
- electroporation may be achieved by energizing an electrode or series of electrodes to produce an electric field.
- a field can be generated in a bipolar or monopolar electrode configuration.
- this field operates to increase the permeabolization of the cell membrane and either (1) reversibly open the cell membrane for a short period of time by causing pores to form in the cell lipid bilayer allowing entry of various therapeutic elements or molecules, after which, when energy application ceases, the pores spontaneously close without killing the cell, or (2) irreversibly opening or porating the cell membrane causing cell instability resulting in cell death utilizing higher intensity (longer or higher energy) pulses, or (3) applying energy in nanosecond pulses resulting in disruption of the intracellular matrix leading to apoptosis and cell death, without causing irreversible poration of the cellular membrane.
- Certain factors determine how a delivered electric field will affect a targeted cell including cell size, cell shape, cell orientation with respect to the applied electric field, cell temperature, distance between cells (cell-cell separation), cell type, tissue heterogeneity, properties of the cellular membrane and the like. Larger cells may be more vulnerable to injury. For example, skeletal muscle cells have been shown to be more susceptible to electrical injury than nearby connective tissue cells (Gaylor et al. (1988) J. Theor. Biol. 133: 223-237). In addition, how cells are oriented within the applied field can make them more susceptible to injury, for example, when the major axis of nonspherical cells is oriented along the electric field, it is more susceptible to rupture (Lee et al. (1987) Plastic and Reconstructive Surgery ______: 672-679.)
- waveforms or shapes of pulses may be applied to achieve electroporation, including sinusoidal AC pulses, DC pulses, square wave pulses, exponentially decaying waveforms or other pulse shapes such as combined AC/DC pulses, or DC shifted RF signals such as those described in Chang, (1989) Biophysical Journal October 56: 641-652, depending on the pulse generator used or the effect desired.
- the parameters of applied energy may be varied, including all or some of the following: waveform shape, amplitude, pulse duration, interval between pulses, number of pulses, combination of waveforms and the like.
- FIGS. 4 and 4 A- 4 B depict a system 10 comprising an electroporation catheter 12 for selective denervation/disruption of nerve tissue.
- the term “catheter” may be used to refer to an elongate element, hollow or solid, flexible or rigid and capable of percutaneous introduction to a body (either by itself, or through a separately created incision or puncture), such as a sheath, a trocar, a needle, a lead.
- voltages may be applied via the electroporation catheter 12 to induce irreversible electroporation, without requiring the use of any other agents to achieve the desired cell destruction and/or denervation.
- any thermal effect may be minimized thereby preventing or minimizing collateral damage to tissues near the target tissues, or the type of physical damage to the nerves themselves that can lead to permanent neuralgia when the nerve fibers generate
- the electroporation or electropermeabilization effect is largely cell-size specific. That is, larger cells will be porated (either reversibly or irreversibly) at lower energy levels than smaller cells. This will allow the denervation effect to be directed at the relatively large nerve cells while sparing smaller adjacent cell types.
- the electric field may be controlled by the size and relative positioning of the electrodes on the treatment device or patient.
- the electroporation catheter system 10 further comprises a pulse generator 14 such as those generators available from Cytopulse Sciences, Inc. (Columbia, Md.); Bio-Rad, Inc. (Hercules, Calif.) (the Gene Pulser Xcell); and IGEA (Carpi, Italy).
- the pulse generator is electrically connected to the catheter 12 which has a proximal end 20 and a distal end 22 and is adapted for either surface placement (cutaneous) or minimally invasive insertion into the desired region of the body as described herein.
- the generator 14 may be modified to produce a higher voltage, increased pulse capacity or other modifications to induce irreversible electroporation.
- the catheter 12 further comprises an electroporation element at the distal end thereof comprising a first electrode 30 and a second axially spaced-apart electrode 32 operatively connected to the pulse generator through cables 34 for delivering the desired number, duration, amplitude and frequency of pulses to affect the targeted nerve tissue.
- the energy delivery parameters can be modified either by the system or the user, depending on the location of the catheter within the body (e.g., the nature of the intervening tissues or structures) and whether a reversible or irreversible cell poration is desired.
- electrodes 30 and 32 may be axially aligned on one side of catheter 12 to produce an electric field concentrated in a lateral direction from the catheter body. Using ring electrodes 30 and 32 as shown in FIG. 4B , creates a more uniform electric field about the shaft of the catheter 12 . Additional monitoring electrode(s), may be located on the catheter 12 .
- FIG. 5A depicts an elongate catheter 50 having a first electrode 52 and second electrode 54 near its distal tip.
- a monitoring or stimulation electrode 56 is disposed in the vicinity of the porating electrodes 52 and 54 for monitoring or localizing the treatment area. In some embodiments, the monitoring or stimulating function may be performed by one or more of the treatment electrodes.
- the catheter 50 may have an optional sharp tip 58 (shown in broken line) to facilitate percutaneous introduction. Electrodes 52 , 54 and 56 are shown as axially aligned on one side of the catheter 50 but could also have ring or other structures.
- FIG. 5B illustrates a steerable catheter 60 adapted to bend or articulate at a region 62 near its distal end.
- Active electrodes 64 and 66 are disposed adjacent to or within the articulated region 62 and a monitoring or stimulation electrode 68 is optionally disposed proximally of the active electrodes.
- Such steering ability enables the operator to introduce the device into tight or tortuous spaces so that optimal placement of the device may be achieved.
- FIG. 5C depicts a catheter 70 that includes an injection element 72 to allow for the injection of a therapeutic agent before, during or after the application of the pulsed energy or electroporation from active electrodes 74 and 76 and monitoring or stimulating electrode 78 .
- the injection element may be a needle as shown in FIG. 5C , an infusion port, or other infusion means.
- a therapeutic agent may be, for example, lidocaine, botulinum toxin (either full or in fragment as detailed copending application No. 11/_______ (Attorney Docket No. 020979-003410US, filed on Jul. 21, 2006, the full disclosure of which has been incorporated herein by reference), capsaicin or a variety of nerve blocking agents.
- the use of the devices and methods of the present invention can increase the effectivity and provide for alternative means of delivery for botulinum toxin to treat pain by inhibiting the release of the neurotransmitter responsible for the transmission of pain, such as various neuropathic diseases and disorders as described in U.S. Pat. Nos. 6,113,915, 6,333,037, 6,372,226, 6,841,156, 6,896,886 and 6,869,610 to Aoki, the contents of which are expressly incorporated herein by reference in their entirety.
- it may be advantageous to heat the targeted cells or surrounding tissue by either applying thermal energy directly to the region, or directing a heated fluid, such as saline to the region through the injection element.
- FIG. 5D depicts a catheter 80 having deployable electrode elements 82 and 84 that are adapted to extend laterally from the main catheter body, and in some cases, penetrate the surrounding tissue prior to application of energy. In doing so the depth and direction of the energy field created by the electroporative process, may be further controlled.
- a stimulating or monitoring electrode 86 may optionally be provided proximally of the active electrodes.
- poration catheters and methods of the present invention in conjunction with a nerve blocking agent, neurotoxin, neurotoxin fragment or other therapeutic agents according to methods and devices described in co-pending patent application no 11/______ (Attorney Docket No. 020979-003410US), filed on Jul. 21, 2006, the full disclosure of which has been incorporated by reference in its entirety.
- the voltage applied to the electrode elements would preferably be in the range applicable to create a reversible electroporation of the nerve or tissue cells, thereby porating the cell to allowing the therapeutic agent to be delivered to achieve the desired effect, but not destroying the cell or otherwise irreversibly damaging the targeted tissue or nerve structures.
- any of the foregoing systems may include electrodes or other monitoring systems either located on the treatment catheter, or external to the patient, to determine the degree of treatment to the region, including, thermocouple, ultrasound transducers, fiberoptics, sensing or stimulating electrodes. Further, it may be desirable to incorporate multiple pairs of electrodes that may be activated in pairs, in groups, or in a sequential manner in order to maximize the desired shape of the lesion while minimizing the field strength requirements. Also, the devices of the present invention may be used in conjunction with more traditional neuromodulation techniques, such as TENS, to mediate pain attributable to the treatment (the presence of which may depend on the level of voltage applied) or neuromuscular response to the applied electric field as further noted in published U.S. application No. 2003/0149451, hereby incorporated by reference in its entirety.
- TENS neuromodulation techniques
- a fully implantable spinal cord modulation system 100 includes an implantable pulse generator 102 which incorporates a power supply or battery as depicted in FIG. 6 .
- the system 100 connects to an implantable lead 104 which includes electrodes 106 and 108 .
- a partially implantable system 120 includes a transmitter 122 , and a receiver 124 that relies upon radio frequency to transmit the energy to the lead or electrode.
- the antenna and transmitter are carried outside the body, while the receiver connected to the lead 126 with electrodes 128 and 130 ) is implanted inside the body.
- FIG. 8 shows the placement of the fully implantable pulse generator 100 device in the region of the sacral plexus of a patient which has been implanted according to the steps set forth in U.S. Pat. No. 6,847,849, previously incorporated by reference herein. Implantation of the partially implantable system 120 could be achieved in the identical manner.
- FIG. 9A depicts a dermal patch 150 having an electrode pair 152 and 154 for delivery of therapeutic energy of the present invention to the targeted region.
- the pad may include one electrode, while the other (a ground) may be positioned elsewhere on the patient's skin (not shown).
- the patch or pad carrying the electrodes should be flexible and conformable and may be formed of a polymer such as silicone, urethane, nylon, polyethylene or other thermoplastic elastomers, or could be substantially rigid and formed of a rigid polymer (such as PEEK or polysulfone)or insulated stainless steel, nickel titanium alloy, or other metal.
- a polymer such as silicone, urethane, nylon, polyethylene or other thermoplastic elastomers
- a rigid polymer such as PEEK or polysulfone
- insulated stainless steel nickel titanium alloy, or other metal.
- various monitoring devices and methods may be employed to track the progress of the therapy.
- algorithms to activate pairs of electrodes or regions of the pad or patch may be employed to enhance the therapeutic effect while reducing the overall power requirements.
- Intraluminal Devices It may further be advantageous to position poration catheters through vessels in the body, particularly arteries to treat adjacent nerves, to direct poration energy to various regions to effect pain reduction.
- Such intraluminal catheters are described in published U.S. applications 2001/0044596 to Jaafar and 2002/0198512 to Seward, hereby incorporated by reference in their entirety, could be used for such energy delivery.
- FIG. 10 illustrates a method for nerve poration by applying energy to the surface of the skin S via the electrode patch 150 .
- FIG. 11 depicts the implantation of electrode lead 104 or 126 that is then operatively connected to the implantable generator and described herein.
- FIG. 12 shows percutaneous nerve poration catheter 12 implanted in a region within the spine. In FIGS. 11 and 12 , the active tip region of the catheter or lead is shown placed alongside the nerve region NR to be treated, but in fact may be positioned within the nerve sheath, or along the spine (SP), or within the muscular layer (MP).
- SP nerve sheath
- MP muscular layer
- a receiver 200 may be placed at the target location (here alongside the nerve region NR in the spine SP), while a transmitter 202 is placed outside or on the skin of the patient.
- a pulse generator in the transmitter 202 may be activated, causing an electric field to be generated in the target area.
- stimulation using one or more electrodes may be used to elicit a nerve response.
- a target treatment location can be confirmed, and then application of poration energy is employed to eliminate or disrupt the nerve and associated pain response, thereby selectively denervating the conduction pathways for the particular type of pain to be treated.
- effects of poration on nerve tissue may be selective due to the cellular structure and orientation of the nerve cells.
- targeted nerve cells may be preferentially affected due to size, sparing smaller or cross-oriented muscle tissue.
- the energy may selectively rupture the nerve cells 220 at ends 222 while the energy dissipates over the main body of the cells.
- poration catheter 12 can be introduced into a lumen of artery A to a location immediately adjacent to a nerve region NR to be treated.
- the catheter 12 will typically be introduced over a guidewire GW under fluoroscopic guidance using well-known intravascular intervention methods and protocols.
- electroporation or other poration energy can be applied across the arterial wall toward the nerve region NR to denervate the nerve as described previously.
- the nerve cells will typically be more susceptible to energy induced damage, the desired temporary or permanent denervation can usually be achieved with minimum or no damage to the artery.
- the catheter 12 can be removed after the treatment session is completed. The treatment can be repeated months or years later if and when nerve function returns.
Abstract
Description
- This application claims the benefit of provisional application No. 60/701,747 (Attorney docket No. 020979-003500US), filed on Jul. 22, 2005, the full disclosure of which is incorporated herein by reference.
- 1. Field of the Invention
- The present invention relates to methods and apparatus for the treatment of nerve function, and more particularly, for selective disruption of conduction pathways in the body for the treatment of pain and other disorders associated with nerve conduction in various regions within the body.
- Approximately 50 million Americans suffer with persistent (chronic) pain. The number of people suffering with chronic pain is higher than the number suffering from serious or terminal illnesses. Yet, unlike major illnesses, most chronic pain is untreated or under-treated. Pain surveys report that 42% of those experiencing chronic pain have such severe pain that they are unable to work, and 63% of pain sufferers are unable to engage in the routine activities of daily life. It has been estimated that among active workers, the loss of productivity from common pain syndromes costs over 60 billion dollars annually. In recent years, consumer advocacy, demographics, and advances in pain control technology have highlighted the clinical need for solutions and advanced the practice of pain management to a priority for healthcare providers.
- Irreversible surgical ablation has been relied upon for the treatment of chronic pain. Lesions are placed on or in the peripheral nerves, spinal chord or brain, but such placement can have side effects such as unintended motor system effects, and required open, surgical procedures. More recently, reversible electrical and localized pharmacologic solutions started to be used.
- Electrical techniques, such as neurostimulation, which deliver a low voltage electrical stimulation to a targeted peripheral nerve or spinal chord to essentially block the sensation of pain as recognized by the brain. First used in the 1960's, electrical stimulation of the peripheral nerves was shown to mask pain with a tingling sensation (paresthesia). This mechanism is part of the “gate control theory of pain” (Melzack and Wall, Science (1965) 150: 971-979.), proposing that a “gate” exists in the spinal chord that controls the transmission of pain signals to the brain. The theory suggests that activation of certain nerve fibers in the dorsal horn of the spinal chord can “close the gate” thereby inhibiting or muting the pain signals.
- A variety of different electrical stimulation techniques have been employed to achieve such blocking of the pain signals, including Transcutaneous Electrical Nerve Stimulation (TENS) which provides non-invasive (skin surface) electrical stimulation to the large mylenated fiber spinal afferents, which functionally blocks nerve signal transmission to essentially create a “short circuit” between the nerve fibers and the sensory pathway to the brain. TENS may be applied to peripheral nerve stimulation, as well as spinal chord stimulation utilizing electrodes placed at the site of the targeted nerve.
- In addition, a technique utilizing stronger electrical stimulation applied to acupuncture needles placed beneath the skin, referred to as Electroacupuncture or Acupuncture Like Transcutaneous Nerve Stimulation (ALTENS), has been employed with the goal of optimizing the release of endorphins and serotonin to combat pain. Various electrical stimulation devices are described in U.S. Pat. Nos. 4,573,481, 3,911,930 and 4,141,365, each of which is hereby incorporated by reference in their entirety.
- The LISS Cranial Stimulator (LCS) and the LISS Body Stimulator (LBS) which deliver a monopolar current at a frequency of 15,000 Hz, modulated at 50 ms “on” and 16.7 ms “off” has been used for pain treatment. (Liss, et al., (1996) Behavioral Science 31: 88-94) U.S. Pat. Nos. 5,983,141 and 6,246,912 to Sluijter describe the application of an electromagnetic signal to neural tissue for pain relief through an electrode to alter the function of the tissue without causing temperatures that are lethal to the tissue.
- Stimulation of the sensory thalamus and periaqueductal or periventricular gray in the deep brain has also shown promise in treating patients that have not been helped by other less invasive modalities of treatment. In this approach, electrodes are placed in the targeted regions of the brain under stereotactic guidance. Stimulation is then applied and when a satisfactory results is achieved, a signal generator may be implanted for long term use. A variety of severe side effects can result from this approach however, including intracerebral hemorrhage and life threatening infections.
- Another approach used widely is orally administered opiates and narcotics, however the systemic effect and addictive nature of the oral medications make them less likely to provide a long term solution. Localized drug delivery or intraspinal drug administration has also shown promise, due to the fact that the approach requires significantly lower doses of narcotics that are delivered directly to the targeted region of the spinal chord either through epidural or intrathecal administration. In these approaches, percutanoues catheters may be placed at the target region, and attached to implantable (subcutaneous) reservoirs or pumps, or external drug pumps. Even though the narcotics are localized, side effects may still present, including impairment of motor function, nausea, constipation, ulcers and other side effects attendant oral narcotic administration.
- Various technologies are currently marketed to treat pain and other motor dysfunctions. Advanced Neuromodulation Systems (Plano, Tex.) manufactures an RF transmitter and probe for spinal chord stimulation as well as an implantable drug delivery system to relieve chronic pain, the latter being described in U.S. Pat. No. 5,938,690, hereby incorporated by reference in its entirety. Vertis Neuroscience (Vancouver, Wash.) provides externally placed, targeted electrode arrays that provide stimulation to the upper and lower back to provide relief to chronic pain referred to as Percutaneous Neuromodulation Therapy (PNT™). Synaptic Corporation (Aurora, Colo.) provides a product for external stimulation for chronic pain by creating electrical impulses along specific sensory nerve pathways to inhibit pain signals to the brain, effect tissue healing, and produce general tissue anesthesia, as further depicted in U.S. Pat. No. 6,161,044, hereby incorporated by reference in its entirety. US2004/0186532 describes an electrode implantable in the brain stem to deliver electrical stimulation to treat pain.
- Additional implantable systems include, a rechargeable spinal chord stimulation system that includes an implantable pulse generator and leads attached to various regions of the spine that are connected to an external remote control or alternative charging system. Such systems are available from Advanced Bionics, a division of Boston Scientific, Natick, Mass. and from Medtronic, Inc. Minneapolis, Minn. Such systems are described in U.S. Pat. No. 6,847,849. The Medtronic system may also include drug delivery technology including intrathecal drug delivery.
- Although promising, many of these systems do not provide a lasting effect, and for some, the therapeutic effect is only felt while the therapy is being administered. The treatment of intractable chronic pain remains a challenge.
- In light of the foregoing, it would be desirable to provide methods and apparatus for treating pain and other disorders associated with nerve conductivity within the human body. The methods and apparatus preferably are minimally invasive or non-invasive, are targeted to specific tissue, such as nerve tissue, and provide a long therapeutic effect. It would further be desirable to provide devices and methods that modify nerve function without necessarily causing permanent physical nerve damage (neuralgia) that can occur once the treated nerve regenerates. At least some of these objectives will be met by the inventions described below.
- All publications and patents or patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent or patent application was specifically and individually so incorporated by reference.
- The present invention provides methods and apparatus for treating pain and other nerve related disorders where the methods and apparatus are minimally or non-invasive, controlled and selective, and/or offer a more durable effect.
- Methods and apparatus according to the present invention treat chronic pain and other neural defects by delivering energy to disrupt nerve tissue at the cellular level to cause permeabolization (poration) of the cell membrane to affect the viability of the nerves at the targeted region. Target nerves include nerves in the spine, particularly cervical, thoracic, lumbar and sacral regions of the spine; peripheral nerves; nerves of the head and neck; and the brain stem. Depending on the amplitude and duration of the applied field, the “poration” of the target nerve may be reversible or irreversible, as desired. Reversible electroporation may be used in conjunction with a nerve blocking agent, chemical or other therapeutic agent to enhance, modify or otherwise modulate disruption of the nerves and/or targeted tissue.
- In one aspect of the present invention methods and apparatus are provided for treating chronic pain and other neural defects by delivering an electric, ultrasonic or other energy field generated by a pulse or pulses of a designated duration and amplitude to disrupt nerve or other tissue at the cellular level via permeabolization of the cell or cell membrane.
- In a further aspect of the invention, the energy may be delivered under conditions selected to cause irreversible cell damage by the creation of pores in the cell membrane which result in the death of the cell. Alternatively, the conditions may be selected to cause reversible or partially reversible cell damage.
- In another aspect of the invention, intracellular electromanipulation of the targeted tissue (such as nerve tissue) using ultrashort electric field pulses leading to apoptosis of the targeted cell may be desirable.
- A further aspect of the invention is to provide methods and apparatus for treating chronic pain and other neural defects by utilizing an electric field to disrupt tissue at the cellular level via permeabolization of the cell causing reversible electroporation of the cellular membrane, preferably by delivering an electric pulse or chain of pulses having a voltage between 40V and 1,000,000V. Such reversible electroporation may be applied in conjunction with a therapeutic agent such as a nerve blocking agent, a neurotoxin or neurotoxin fragment, such as the light chain portion of botulinim toxin serotype A.
- In a further aspect of the invention, it may be desirable to provide methods and devices that selectively disrupt certain cell types and not others, to provide a therapy that can be applied from multiple locations within the body.
- In a preferred aspect of the present invention, the target nerves are frequently located adjacent to arteries which can be used for percutaneous access to the nerves for example, vascular catheters having electrodes, ultrasonic transducers, or other energy sources at their distal ends may be advanced through an artery to an arterial site adjacent to the target nerve which often runs directly along the outside of the artery energy can be applied which denervates the nerve while leaving the arterial wall intact as the nerve cells are more susceptible to injury. Thus, a single treatment can damage the adjacent nerve for extended periods of months or more without damaging the artery used for access.
- Examples of arteries that can be used to access particular target nerves of the body regions include:
Artery Nerve Carotid Cranio-facial Vertebral Cranio-facial Radial Peripheral (Arms and Hands) Femoral Lower limbs, Sciatica, Disc Pain Popliteal Lower limbs, Sciatica, Disc Pain - In a specific aspect of the present invention, patients suffering from refactory angina may be treated by reversible or irreversible disruption of the stellate ganglion in the neck in the area of the C6 vertebra (
FIG. 1B ) and/or of the paravertebral nerves in the spine in the area of the T6 vertebra (FIG. 1B ). The stellate ganglion and associated nerves can be treated or denervated by passing a nerve poration catheter into the common, internal or external arteries, placing the treatment electrode(s) or other component adjacent the nerve level to be treated, and delivering energy to cause irreversible poration to the target nerves. Some nerves may be better accessed via catheter placement in the vertebral or subclavian arteries. Nerves in the area of T6 can be accessed by placing the treatment catheter in the aorta, anterior or posterior spinal arteries, radicular arteries, intercostal arteries, or medullary arteries. - The examples of arteries accessed and nerves treated to address various pain syndromes should be considered exemplary in nature and not limiting. It should be recognized that any syndrome which is amenable by treatment by denervation will be amenable to treatment via by the inventive technology.
- Further features of the invention, its nature and various advantages will be more apparent from the accompanying drawings and the following detailed description, in which:
-
FIG. 1A —depicts a Dermatome showing areas of the body (skin) supplied by corresponding nerve fibers on front of body; -
FIG. 1B —depicts a Dermatome showing areas of the body (skin) supplied by corresponding nerve fibers on rear of body; -
FIG. 2 —depicts a side view of three vertebrae in a vertebral column showing certain relationships between spinal nerve roots and vertebrae; -
FIG. 3 —depicts a schematic of spinal nerve and vertebrae. -
FIG. 4 —depicts a generator and catheter system capable of supply pulsed electric fields to effect reversible or irreversible electroporation in targeted cells. -
FIG. 4A and 4B—depict catheter distal tips of the present invention in various configurations showing spaced apart electrodes, including an optional monitoring electrode. - FIGS. 5A-D—depict various electrode catheter configurations adapted to deliver energy or energy and therapeutic agents to target tissue.
-
FIG. 6 —depicts a fully implantable pulse generator and lead of the present invention. -
FIG. 7 —depicts an implantable receiver and external transmitter and controller for delivering energy according to the present invention. -
FIG. 8 —depicts a schematic representing placement of the implantable version of the present invention. -
FIGS. 9A and B—depict an electrode pad for placement on the skin of a patient, including one or multiple circuits, either smooth or incorporating microneedles. -
FIG. 10 —depicts a method of use of the invention according toFIGS. 9A and 9B . -
FIG. 11 —depicts a method of use of the invention according toFIG. 6 . -
FIG. 12 —depicts a method of use of the invention according toFIGS. 5A-5D . -
FIG. 13 —depicts a method of use of the invention according toFIG. 7 . -
FIG. 14 —depicts a schematic of a nerve fiber showing the relative cell size allowing selective cell permeabolization of nerve cells. -
FIG. 15 —depicts a schematic of a target nerve region being treated by a poration catheter in an adjacent artery. - The present invention is directed to methods and apparatus for targeting, stimulating, and disrupting nerve tissue, or tissue adjacent nerve tissue (collectively “target tissue”) usually at the cellular level, in order to selectively denervate or disrupt nerves and nerve pathways responsible for creating a pain response in a mammalian body. Target tissue may be treated from one or more locations either adjacent to or at a distance from target tissue. The target tissue may include the nerve directly associated with the pain response and/or conduction pathways contributing directly or indirectly to the pain response.
- Pain syndromes that may be treated utilizing the present invention include, neuropathic and nociceptive pain, for example, musculoskeletal pain (back, neck shoulder), myofascial (muscle) pain, neuropathic pain (complex regional pain syndrome, central pain syndrome, neuralgia, neuropathy), headaches, cancer pain, fibromyalgia, pelvic pain, arachnoiditis, arthritis, facial pain (TMJ, Temporomandibular disorders (TMD)), sciatica, skin disorders (burn pain, shingles, herpes, tumors, vasculitis), spacicity, spinal chord injury or stenosis, sickle cell disease, and pain associated with vascular disease, both peripheral and cardiac.
- The body's nervous system consists of the central nervous system (brain), spinal chord nerves and the peripheral nervous system (sensory nerve fibers and motor nerve fibers outside of the brain and spinal chord). The system includes nerves (bundles of axons enclosed in connective tissue) and can be characterized as sensory/afferent, motor/efferent, or a combination of both sensory and motor fibers. The spinal nerves include fused nerve roots, for example, the dorsal root nerves are associated with sensory functions, and the ventral root nerves are associated with motor functions. Peripheral nerves may be cranial (arising from the brain), or spinal (arising from the spinal column), and are usually associated with sensations or motor functions in the hands, arms, legs or feet.
- Cranial nerves are mostly associated with motor function, or a combination of motor and sensory functions. As shown in
FIG. 2 , the spinal nerves consist of 31 pairs of nerves organized into various regions along the spine the cervical (C), thoracic (T), lumbar (L), and sacral (S). The spinal nerves are further organized into nerve networks or nerve plexus including C1-C4 (cervical plexus), C5-C8 and T1 (brachial plexus), L1-14 (lumbar plexus), and L4-S4 (sacral plexus). The relationship between the spinal nerve and the muscle (myotome) and between spinal nerve and skin (dermatome) are depicted inFIGS. 1A and 1B, showing the nerves associated with the particular region of the body. In treating pain or other disorders associated with nerve conduction in the body, devices can target a relatively localized region of the spinal column depending on the type of pain or motor function and location of pain or motor function (dermatome or myotome) to be treated. - Devices of the present invention may be directed to “targeted regions” such as cervical, thoracic, lumbar and sacral regions of the spine, peripheral nerves, nerves of the head and neck, brain stem, and deep brain. Some particular examples include, spinal chord modulation for chronic pain (for example application of energy of the present invention to the region of the spine at L1-L5 to treat lower limb and/or back pain), peripheral nerve modulation for chronic pain (for example the radial or ulnar nerve to treat hand or finger pain or dysesthesias.), and sacral nerve modulation to treat pelvic pain. In some instances, the devices and methods of the present invention may also be employed to treat certain motor dysfunctions; for example, spinal chord nerve modulation to treat peripheral vascular disease (PVD), deep brain nerve modulation for tremor, Parkinsons, depression, obsessive compulsive disorder, motor dysfunction, and brain injury, and vagus nerve modulation for treatment of epilepsy, or obesity.
- High Voltage Pulsed Electric Fields. To achieve the goals of the present invention, it may be desirable to employ methods and apparatus for achieving nerve modulation and/or denervation utilizing pulsed electric fields and/or electroporation applied directly to the targeted region or in proximity to the targeted region to produce the desired denervation or nerve disruption. For purposes of this disclosure, the term “electroporation” can encompass the use of pulsed electric fields (PEFs), nanosecond pulsed electric fields (nsPEFs), ionophoreseis, electrophoresis, electropermeabilization, sonoporation and/or combinations thereof, permanent or temporary, reversible or irreversible, with or without the use of adjuctive agents, without necessitating the presence of a thermal effect. Similarly, the term “electrode” used herein, encompasses the use of various types of energy producing devices, including antennas (microwave transmitters) and ultrasonic elements. In practice, sonoporation, cell membrane manipulation by application of ultrasonic energy, may have advantages in performing the therapeutic treatment of the present invention due to its ability to manipulate the membrane without producing as much heat at the treatment site as other energy modalities that have been used, and its ability to focus at a specific treatment site.
- The methods and apparatus of the present invention can employ reversible electroporationof the type used in medicine and biology to transfer chemicals, drugs, genes and other molecules into targeted cells for a variety of purposes such as electrochemotherapy, gene transfer, transdermal drug delivery, vaccines, and the like. Irreversible electroporation may also be employed as used for cell separation in debacterilization of water and food, stem cell enrichment and cancer cell purging (U.S. Pat. No. 6,043,066 to Mangano), directed ablation of neoplastic prostate tissues (US2003/0060856 to Chornenky), treatment of restenosis in body vessels (US2001/0044596 to Jaafar), selective irreversible electroporation of fat cells (US 2004/0019371 to Jaafar) and ablation of tumors (Davalos, et al. Annals of Biomedical Engineering 33: 223-321. The entire contents of each of these references are expressly incorporated herein by reference.
- Energy fields applied in ultrashort pulses, or nanosecond pulsed electric fields (nsPEFs) may also be used to porate target nerve and other cells in accordance with the present invention. Ultrashort pulse lengths are directed at target subcellular structures without permanently disrupting the outer membrane. An example of this technology is described by Schoenbach et al. (2001) J. Bioelectromagnetics 22: 440-448, and in U.S. Pat. No. 6,326,177, the contents of which is expressly herein incorporated by reference. The short pulses target the intracellular apparatus, and although the cell membrane may exhibit an electroporative effect, such effect is reversible and does not lead to permanent membrane disruption. Following application of nanosecond pulses, apoptosis is induced in the intracellular contents, affecting the cell's viability (for example limiting the ability to reproduce).
- In a specific embodiment of the present invention, electroporation may be achieved by energizing an electrode or series of electrodes to produce an electric field. Such a field can be generated in a bipolar or monopolar electrode configuration. When applied to cells, depending on the duration and strength of the applied pulses, this field operates to increase the permeabolization of the cell membrane and either (1) reversibly open the cell membrane for a short period of time by causing pores to form in the cell lipid bilayer allowing entry of various therapeutic elements or molecules, after which, when energy application ceases, the pores spontaneously close without killing the cell, or (2) irreversibly opening or porating the cell membrane causing cell instability resulting in cell death utilizing higher intensity (longer or higher energy) pulses, or (3) applying energy in nanosecond pulses resulting in disruption of the intracellular matrix leading to apoptosis and cell death, without causing irreversible poration of the cellular membrane. As characterized by Weaver (1993), Journal of Cellular Biochemistry 51: 426-435, short(1-100 μs) and longer (1-10 ms) pulses have induced electroporation in a variety of cell types. In a single cell model, most cells will exhibit electroporation in the range of 1-1.5 V applied across the cell (membrane potential).
- Certain factors determine how a delivered electric field will affect a targeted cell, including cell size, cell shape, cell orientation with respect to the applied electric field, cell temperature, distance between cells (cell-cell separation), cell type, tissue heterogeneity, properties of the cellular membrane and the like. Larger cells may be more vulnerable to injury. For example, skeletal muscle cells have been shown to be more susceptible to electrical injury than nearby connective tissue cells (Gaylor et al. (1988) J. Theor. Biol. 133: 223-237). In addition, how cells are oriented within the applied field can make them more susceptible to injury, for example, when the major axis of nonspherical cells is oriented along the electric field, it is more susceptible to rupture (Lee et al. (1987) Plastic and Reconstructive Surgery ______: 672-679.)
- Various waveforms or shapes of pulses may be applied to achieve electroporation, including sinusoidal AC pulses, DC pulses, square wave pulses, exponentially decaying waveforms or other pulse shapes such as combined AC/DC pulses, or DC shifted RF signals such as those described in Chang, (1989) Biophysical Journal October 56: 641-652, depending on the pulse generator used or the effect desired. The parameters of applied energy may be varied, including all or some of the following: waveform shape, amplitude, pulse duration, interval between pulses, number of pulses, combination of waveforms and the like.
- Catheter Devices.
FIGS. 4 and 4 A-4B depict asystem 10 comprising anelectroporation catheter 12 for selective denervation/disruption of nerve tissue. For purposes of this specification, the term “catheter” may be used to refer to an elongate element, hollow or solid, flexible or rigid and capable of percutaneous introduction to a body (either by itself, or through a separately created incision or puncture), such as a sheath, a trocar, a needle, a lead. In certain configurations of the present invention, voltages may be applied via theelectroporation catheter 12 to induce irreversible electroporation, without requiring the use of any other agents to achieve the desired cell destruction and/or denervation. It is a further advantage of this type of energy that any thermal effect may be minimized thereby preventing or minimizing collateral damage to tissues near the target tissues, or the type of physical damage to the nerves themselves that can lead to permanent neuralgia when the nerve fibers generate A further advantage of this type of energy is that the electroporation or electropermeabilization effect is largely cell-size specific. That is, larger cells will be porated (either reversibly or irreversibly) at lower energy levels than smaller cells. This will allow the denervation effect to be directed at the relatively large nerve cells while sparing smaller adjacent cell types. In addition, the electric field may be controlled by the size and relative positioning of the electrodes on the treatment device or patient. - The
electroporation catheter system 10 further comprises apulse generator 14 such as those generators available from Cytopulse Sciences, Inc. (Columbia, Md.); Bio-Rad, Inc. (Hercules, Calif.) (the Gene Pulser Xcell); and IGEA (Carpi, Italy). The pulse generator is electrically connected to thecatheter 12 which has aproximal end 20 and adistal end 22 and is adapted for either surface placement (cutaneous) or minimally invasive insertion into the desired region of the body as described herein. Thegenerator 14 may be modified to produce a higher voltage, increased pulse capacity or other modifications to induce irreversible electroporation. Thecatheter 12 further comprises an electroporation element at the distal end thereof comprising afirst electrode 30 and a second axially spaced-apartelectrode 32 operatively connected to the pulse generator throughcables 34 for delivering the desired number, duration, amplitude and frequency of pulses to affect the targeted nerve tissue. The energy delivery parameters can be modified either by the system or the user, depending on the location of the catheter within the body (e.g., the nature of the intervening tissues or structures) and whether a reversible or irreversible cell poration is desired. For example energy in the range of 10 V/cm to 104 V/cm for a duration of 10 μs to 100 ms may be used to achieve reversible electroporation and in the range of 100 V/cm to 106 V/cm for a duration of 10 μsec to 100 msec to achieve irreversible electroporation or apoptosis. As shown inFIG. 4A ,electrodes catheter 12 to produce an electric field concentrated in a lateral direction from the catheter body. Usingring electrodes FIG. 4B , creates a more uniform electric field about the shaft of thecatheter 12. Additional monitoring electrode(s), may be located on thecatheter 12. - Further catheter devices and electrode configurations are shown in
FIGS. 5A-5D .FIG. 5A depicts anelongate catheter 50 having afirst electrode 52 andsecond electrode 54 near its distal tip. A monitoring orstimulation electrode 56 is disposed in the vicinity of theporating electrodes catheter 50 may have an optional sharp tip 58 (shown in broken line) to facilitate percutaneous introduction.Electrodes catheter 50 but could also have ring or other structures. -
FIG. 5B illustrates asteerable catheter 60 adapted to bend or articulate at aregion 62 near its distal end.Active electrodes region 62 and a monitoring orstimulation electrode 68 is optionally disposed proximally of the active electrodes. Such steering ability enables the operator to introduce the device into tight or tortuous spaces so that optimal placement of the device may be achieved. -
FIG. 5C depicts acatheter 70 that includes aninjection element 72 to allow for the injection of a therapeutic agent before, during or after the application of the pulsed energy or electroporation fromactive electrodes electrode 78. The injection element may be a needle as shown inFIG. 5C , an infusion port, or other infusion means. Such a therapeutic agent may be, for example, lidocaine, botulinum toxin (either full or in fragment as detailed copending application No. 11/______ (Attorney Docket No. 020979-003410US, filed on Jul. 21, 2006, the full disclosure of which has been incorporated herein by reference), capsaicin or a variety of nerve blocking agents. The use of the devices and methods of the present invention can increase the effectivity and provide for alternative means of delivery for botulinum toxin to treat pain by inhibiting the release of the neurotransmitter responsible for the transmission of pain, such as various neuropathic diseases and disorders as described in U.S. Pat. Nos. 6,113,915, 6,333,037, 6,372,226, 6,841,156, 6,896,886 and 6,869,610 to Aoki, the contents of which are expressly incorporated herein by reference in their entirety. Further, to aid the electroporation process, it may be advantageous to heat the targeted cells or surrounding tissue by either applying thermal energy directly to the region, or directing a heated fluid, such as saline to the region through the injection element. -
FIG. 5D depicts acatheter 80 havingdeployable electrode elements monitoring electrode 86 may optionally be provided proximally of the active electrodes. - In certain configurations it may be advantageous to use the poration catheters and methods of the present invention in conjunction with a nerve blocking agent, neurotoxin, neurotoxin fragment or other therapeutic agents according to methods and devices described in co-pending patent application no 11/______ (Attorney Docket No. 020979-003410US), filed on Jul. 21, 2006, the full disclosure of which has been incorporated by reference in its entirety. In this instance, the voltage applied to the electrode elements would preferably be in the range applicable to create a reversible electroporation of the nerve or tissue cells, thereby porating the cell to allowing the therapeutic agent to be delivered to achieve the desired effect, but not destroying the cell or otherwise irreversibly damaging the targeted tissue or nerve structures.
- Any of the foregoing systems may include electrodes or other monitoring systems either located on the treatment catheter, or external to the patient, to determine the degree of treatment to the region, including, thermocouple, ultrasound transducers, fiberoptics, sensing or stimulating electrodes. Further, it may be desirable to incorporate multiple pairs of electrodes that may be activated in pairs, in groups, or in a sequential manner in order to maximize the desired shape of the lesion while minimizing the field strength requirements. Also, the devices of the present invention may be used in conjunction with more traditional neuromodulation techniques, such as TENS, to mediate pain attributable to the treatment (the presence of which may depend on the level of voltage applied) or neuromuscular response to the applied electric field as further noted in published U.S. application No. 2003/0149451, hereby incorporated by reference in its entirety.
- Implantable Devices. A fully implantable spinal
cord modulation system 100 includes animplantable pulse generator 102 which incorporates a power supply or battery as depicted inFIG. 6 . Thesystem 100 connects to animplantable lead 104 which includes electrodes 106 and 108. As shown inFIG. 7 , a partially implantable system 120 includes a transmitter 122, and a receiver 124 that relies upon radio frequency to transmit the energy to the lead or electrode. In this system the antenna and transmitter are carried outside the body, while the receiver connected to thelead 126 with electrodes 128 and 130) is implanted inside the body.FIG. 8 shows the placement of the fullyimplantable pulse generator 100 device in the region of the sacral plexus of a patient which has been implanted according to the steps set forth in U.S. Pat. No. 6,847,849, previously incorporated by reference herein. Implantation of the partially implantable system 120 could be achieved in the identical manner. - Cutaneous or Subcutaneous Devices. For some conditions, it may be desirable to apply the poration energy from the surface of the skin (transcutaneously), or from just below the skin (subcutaneously).
FIG. 9A depicts adermal patch 150 having anelectrode pair FIG. 9B , such electrodes may be in the form ofmicroneedles 160 that puncture the skin some distance to deliver the therapeutic energy of the present invention subcutaneously. The patch or pad carrying the electrodes should be flexible and conformable and may be formed of a polymer such as silicone, urethane, nylon, polyethylene or other thermoplastic elastomers, or could be substantially rigid and formed of a rigid polymer (such as PEEK or polysulfone)or insulated stainless steel, nickel titanium alloy, or other metal. As noted above, various monitoring devices and methods may be employed to track the progress of the therapy. Similarly, algorithms to activate pairs of electrodes or regions of the pad or patch may be employed to enhance the therapeutic effect while reducing the overall power requirements. - Intraluminal Devices. It may further be advantageous to position poration catheters through vessels in the body, particularly arteries to treat adjacent nerves, to direct poration energy to various regions to effect pain reduction. Such intraluminal catheters are described in published U.S. applications 2001/0044596 to Jaafar and 2002/0198512 to Seward, hereby incorporated by reference in their entirety, could be used for such energy delivery.
- Methods of Use.
FIG. 10 illustrates a method for nerve poration by applying energy to the surface of the skin S via theelectrode patch 150.FIG. 11 depicts the implantation ofelectrode lead FIG. 12 shows percutaneousnerve poration catheter 12 implanted in a region within the spine. InFIGS. 11 and 12 , the active tip region of the catheter or lead is shown placed alongside the nerve region NR to be treated, but in fact may be positioned within the nerve sheath, or along the spine (SP), or within the muscular layer (MP). - In yet another embodiment shown in
FIG. 13 , areceiver 200 may be placed at the target location (here alongside the nerve region NR in the spine SP), while a transmitter 202 is placed outside or on the skin of the patient. Once in place adjacent the nerve region NR to be treated, a pulse generator in the transmitter 202 may be activated, causing an electric field to be generated in the target area. Prior to activation of therapeutic voltages, once the catheter(s) have been appropriately positioned, stimulation using one or more electrodes may be used to elicit a nerve response. By observing the nerve reflex, a target treatment location can be confirmed, and then application of poration energy is employed to eliminate or disrupt the nerve and associated pain response, thereby selectively denervating the conduction pathways for the particular type of pain to be treated. - In operation, effects of poration on nerve tissue may be selective due to the cellular structure and orientation of the nerve cells. For example as shown in
FIG. 14 , targeted nerve cells may be preferentially affected due to size, sparing smaller or cross-oriented muscle tissue. As shown, the energy may selectively rupture thenerve cells 220 at ends 222 while the energy dissipates over the main body of the cells. - As shown in
FIG. 15 ,poration catheter 12 can be introduced into a lumen of artery A to a location immediately adjacent to a nerve region NR to be treated. Thecatheter 12 will typically be introduced over a guidewire GW under fluoroscopic guidance using well-known intravascular intervention methods and protocols. Once in place, electroporation or other poration energy can be applied across the arterial wall toward the nerve region NR to denervate the nerve as described previously. As the nerve cells will typically be more susceptible to energy induced damage, the desired temporary or permanent denervation can usually be achieved with minimum or no damage to the artery. Thecatheter 12 can be removed after the treatment session is completed. The treatment can be repeated months or years later if and when nerve function returns. - Although various illustrative embodiments of the present invention are described above, it will be evident to one skilled in the art that various changes and modifications may be made without departing from the scope of the invention. It will also be apparent that various changes and modifications may be made herein without departing from the invention. The appended claims are intended to cover all such changes and modifications that fall within the true spirit and scope of the invention.
Claims (30)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/459,582 US20070021803A1 (en) | 2005-07-22 | 2006-07-24 | Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction |
US12/567,521 US8504147B2 (en) | 2005-07-22 | 2009-09-25 | Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction |
US13/930,500 US8676309B2 (en) | 2005-07-22 | 2013-06-28 | Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction |
US14/162,210 US8989859B2 (en) | 2005-07-22 | 2014-01-23 | Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction |
US14/613,971 US9345538B2 (en) | 2005-07-22 | 2015-02-04 | Systems and methods for neuromodulation for treatment of disorders associated with nerve conduction |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70174705P | 2005-07-22 | 2005-07-22 | |
US11/459,582 US20070021803A1 (en) | 2005-07-22 | 2006-07-24 | Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/567,521 Continuation US8504147B2 (en) | 2005-07-22 | 2009-09-25 | Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070021803A1 true US20070021803A1 (en) | 2007-01-25 |
Family
ID=37680083
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/459,582 Abandoned US20070021803A1 (en) | 2005-07-22 | 2006-07-24 | Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction |
US12/567,521 Active 2027-02-26 US8504147B2 (en) | 2005-07-22 | 2009-09-25 | Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction |
US13/930,500 Expired - Fee Related US8676309B2 (en) | 2005-07-22 | 2013-06-28 | Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction |
US14/162,210 Active US8989859B2 (en) | 2005-07-22 | 2014-01-23 | Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction |
US14/613,971 Active US9345538B2 (en) | 2005-07-22 | 2015-02-04 | Systems and methods for neuromodulation for treatment of disorders associated with nerve conduction |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/567,521 Active 2027-02-26 US8504147B2 (en) | 2005-07-22 | 2009-09-25 | Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction |
US13/930,500 Expired - Fee Related US8676309B2 (en) | 2005-07-22 | 2013-06-28 | Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction |
US14/162,210 Active US8989859B2 (en) | 2005-07-22 | 2014-01-23 | Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction |
US14/613,971 Active US9345538B2 (en) | 2005-07-22 | 2015-02-04 | Systems and methods for neuromodulation for treatment of disorders associated with nerve conduction |
Country Status (1)
Country | Link |
---|---|
US (5) | US20070021803A1 (en) |
Cited By (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060222667A1 (en) * | 2003-05-13 | 2006-10-05 | The Foundry, Inc. | Apparatus for treating asthma using neurotoxin |
US20070267011A1 (en) * | 2006-05-19 | 2007-11-22 | The Foundry Inc. | Apparatus for toxin delivery to the nasal cavity |
US20080154333A1 (en) * | 2005-09-26 | 2008-06-26 | Venturi Group, Llc | Neural blocking therapy |
US20080281313A1 (en) * | 2007-05-08 | 2008-11-13 | Randy Fagin | System and Method for Laparoscopic Nerve Detection |
US20080306325A1 (en) * | 2006-10-02 | 2008-12-11 | Emkinetics | Method and apparatus for magnetic induction therapy |
US20090204173A1 (en) * | 2007-11-05 | 2009-08-13 | Zi-Ping Fang | Multi-Frequency Neural Treatments and Associated Systems and Methods |
US20090269317A1 (en) * | 2008-04-29 | 2009-10-29 | Davalos Rafael V | Irreversible electroporation to create tissue scaffolds |
US20090306644A1 (en) * | 2008-05-09 | 2009-12-10 | Innovative Pulmonary Solutions, Inc. | Systems, assemblies, and methods for treating a bronchial tree |
WO2010065146A1 (en) * | 2008-12-05 | 2010-06-10 | Ndi Medical, Llc | Systems and methods to place one or more leads in tissue to electrically stimulate nerves of passage to treat pain |
US20100143413A1 (en) * | 2008-08-14 | 2010-06-10 | The Cleveland Clinic Foundation | Apparatus and method for treating a neuromuscular defect |
US20100160712A1 (en) * | 2006-10-02 | 2010-06-24 | Daniel Rogers Burnett | Method and apparatus for magnetic induction therapy |
US20100191307A1 (en) * | 2009-01-29 | 2010-07-29 | Zi-Ping Fang | Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions |
WO2010118387A1 (en) * | 2009-04-09 | 2010-10-14 | Virginia Tech Intellectual Properties, Inc. | Integration of very short electric pulses for minimally to noninvasive electroporation |
US20100274317A1 (en) * | 2009-04-22 | 2010-10-28 | Jon Parker | Devices for controlling high frequency spinal cord modulation for inhibiting pain, and associated systems and methods, including simplified contact selection |
US7837719B2 (en) | 2002-05-09 | 2010-11-23 | Daemen College | Electrical stimulation unit and waterbath system |
US20100331758A1 (en) * | 2008-04-29 | 2010-12-30 | Davalos Rafael V | Irreversible electroporation using nanoparticles |
US20110021863A1 (en) * | 2009-07-24 | 2011-01-27 | Daniel Rogers Burnett | Cooling systems and methods for conductive coils |
US20110118725A1 (en) * | 2009-11-11 | 2011-05-19 | Mayse Martin L | Non-invasive and minimally invasive denervation methods and systems for performing the same |
US20110152855A1 (en) * | 2009-10-27 | 2011-06-23 | Mayse Martin L | Delivery devices with coolable energy emitting assemblies |
US20110307029A1 (en) * | 2008-08-06 | 2011-12-15 | Cerephex Corporation | Brain stimulation methods for treating central sensitivity |
US8133497B2 (en) | 2005-07-22 | 2012-03-13 | The Foundry, Llc | Systems and methods for delivery of a therapeutic agent |
US20120130369A1 (en) * | 2009-05-04 | 2012-05-24 | Ruggero Cadossi | Reversible electroporation device for inducing cell apoptosis |
US20120310140A1 (en) * | 2010-12-01 | 2012-12-06 | Spinal Modulation, Inc. | Directed delivery of agents to neural anatomy |
EP2561906A1 (en) * | 2011-08-25 | 2013-02-27 | Nihon Kohden Corporation | Pain sensory nerve stimulation apparatus |
US8483831B1 (en) | 2008-02-15 | 2013-07-09 | Holaira, Inc. | System and method for bronchial dilation |
US8588884B2 (en) | 2010-05-28 | 2013-11-19 | Emkinetics, Inc. | Microneedle electrode |
US8649874B2 (en) | 2010-11-30 | 2014-02-11 | Nevro Corporation | Extended pain relief via high frequency spinal cord modulation, and associated systems and methods |
US8676331B2 (en) | 2012-04-02 | 2014-03-18 | Nevro Corporation | Devices for controlling spinal cord modulation for inhibiting pain, and associated systems and methods, including controllers for automated parameter selection |
ITMO20120275A1 (en) * | 2012-11-13 | 2014-05-14 | Claudio Reverberi | PERCUTANEOUS ELECTRODE FOR MIDOLLAR NEUROSTIMULATION. |
US8880189B2 (en) | 2011-02-23 | 2014-11-04 | John D. LIPANI | System and method for electrical stimulation of the lumbar vertebral column |
US8989859B2 (en) | 2005-07-22 | 2015-03-24 | Medtronic Ardian Luxembourg S.A.R.L. | Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction |
US9002477B2 (en) | 2006-01-17 | 2015-04-07 | Emkinetics, Inc. | Methods and devices for performing electrical stimulation to treat various conditions |
US9005102B2 (en) | 2006-10-02 | 2015-04-14 | Emkinetics, Inc. | Method and apparatus for electrical stimulation therapy |
WO2013177006A3 (en) * | 2012-05-21 | 2015-06-18 | Stimwave Technologies, Incorporated | Methods and devices for modulating excitable tissue of the exiting spinal nerves |
US9149328B2 (en) | 2009-11-11 | 2015-10-06 | Holaira, Inc. | Systems, apparatuses, and methods for treating tissue and controlling stenosis |
US9198733B2 (en) | 2008-04-29 | 2015-12-01 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for electroporation-based therapies |
US20160045735A1 (en) * | 2013-10-09 | 2016-02-18 | GiMer Medical Co., Ltd. | Electronic stimulation device, method of treatment and electronic stimulation system |
US9278215B2 (en) | 2011-09-08 | 2016-03-08 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods |
US9283051B2 (en) | 2008-04-29 | 2016-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating a treatment volume for administering electrical-energy based therapies |
US20160074626A1 (en) * | 2014-09-15 | 2016-03-17 | Ethicon, Inc. | System and Method for Targeted Delivery of Therapeutic Agents to Tissue |
US20160096022A1 (en) * | 2014-10-01 | 2016-04-07 | GiMer Medical Co., Ltd. | Electronic stimulation system and device thereof for dorsal root ganglion |
US9339641B2 (en) | 2006-01-17 | 2016-05-17 | Emkinetics, Inc. | Method and apparatus for transdermal stimulation over the palmar and plantar surfaces |
US9398933B2 (en) | 2012-12-27 | 2016-07-26 | Holaira, Inc. | Methods for improving drug efficacy including a combination of drug administration and nerve modulation |
US9409019B2 (en) | 2009-07-28 | 2016-08-09 | Nevro Corporation | Linked area parameter adjustment for spinal cord stimulation and associated systems and methods |
US20170056653A1 (en) * | 2013-10-09 | 2017-03-02 | GiMer Medical Co., Ltd. | Method for reducing overactive bladder syndrome and computer-readable medium thereof |
US9630011B2 (en) | 2011-02-23 | 2017-04-25 | John D Lipani | System and methods for diagnosis and treatment of discogenic lower back pain |
US9707394B2 (en) | 2010-11-11 | 2017-07-18 | Spr Therapeutics, Llc | Systems and methods for the treatment of pain through neural fiber stimulation generating a stochastic response |
US9724535B1 (en) * | 2013-02-19 | 2017-08-08 | Blugreen Technologies, Inc. | Low frequency magnetic pulse variable resonator for actively influencing the interaction and intercommunication at the cellular level for biological organisms and molecular level of matter |
US9757196B2 (en) | 2011-09-28 | 2017-09-12 | Angiodynamics, Inc. | Multiple treatment zone ablation probe |
US9770593B2 (en) | 2012-11-05 | 2017-09-26 | Pythagoras Medical Ltd. | Patient selection using a transluminally-applied electric current |
US9833614B1 (en) | 2012-06-22 | 2017-12-05 | Nevro Corp. | Autonomic nervous system control via high frequency spinal cord modulation, and associated systems and methods |
KR20170136021A (en) * | 2009-04-16 | 2017-12-08 | 이노비오 파마수티컬즈, 인크. | Contactless electropermeabilization electrode and method |
US9867652B2 (en) | 2008-04-29 | 2018-01-16 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds |
US9884189B2 (en) | 2008-12-05 | 2018-02-06 | Spr Therapeutics, Inc. | Systems and methods to place one or more leads in tissue for providing functional and/or therapeutic stimulation |
US9888956B2 (en) | 2013-01-22 | 2018-02-13 | Angiodynamics, Inc. | Integrated pump and generator device and method of use |
US9895189B2 (en) | 2009-06-19 | 2018-02-20 | Angiodynamics, Inc. | Methods of sterilization and treating infection using irreversible electroporation |
US9895539B1 (en) | 2013-06-10 | 2018-02-20 | Nevro Corp. | Methods and systems for disease treatment using electrical stimulation |
US9956408B2 (en) | 2013-10-09 | 2018-05-01 | Gimer Medical Co. Ltd. | Method for reducing spasticity and non-transitory computer-readable medium thereof |
CN108014419A (en) * | 2016-11-04 | 2018-05-11 | 精能医学股份有限公司 | Electrical stimulation device and signal generating method, non-transient computer-readable storage media |
US10004557B2 (en) | 2012-11-05 | 2018-06-26 | Pythagoras Medical Ltd. | Controlled tissue ablation |
US10016600B2 (en) | 2013-05-30 | 2018-07-10 | Neurostim Solutions, Llc | Topical neurological stimulation |
US10052465B2 (en) | 2005-07-22 | 2018-08-21 | The Foundry, Llc | Methods and systems for toxin delivery to the nasal cavity |
US10076663B2 (en) | 2010-11-11 | 2018-09-18 | Spr Therapeutics, Inc. | Systems and methods for the treatment of pain through neural fiber stimulation |
US10117707B2 (en) | 2008-04-29 | 2018-11-06 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
US10149978B1 (en) | 2013-11-07 | 2018-12-11 | Nevro Corp. | Spinal cord modulation for inhibiting pain via short pulse width waveforms, and associated systems and methods |
US10154874B2 (en) | 2008-04-29 | 2018-12-18 | Virginia Tech Intellectual Properties, Inc. | Immunotherapeutic methods using irreversible electroporation |
US10183165B2 (en) | 2013-10-09 | 2019-01-22 | GiMer Medical Co., Ltd. | Method of reducing renal hypertension and computer-readable medium |
US10238447B2 (en) | 2008-04-29 | 2019-03-26 | Virginia Tech Intellectual Properties, Inc. | System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress |
US10272178B2 (en) | 2008-04-29 | 2019-04-30 | Virginia Tech Intellectual Properties Inc. | Methods for blood-brain barrier disruption using electrical energy |
US10292755B2 (en) | 2009-04-09 | 2019-05-21 | Virginia Tech Intellectual Properties, Inc. | High frequency electroporation for cancer therapy |
US10383685B2 (en) | 2015-05-07 | 2019-08-20 | Pythagoras Medical Ltd. | Techniques for use with nerve tissue |
US10471254B2 (en) | 2014-05-12 | 2019-11-12 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
US10478249B2 (en) | 2014-05-07 | 2019-11-19 | Pythagoras Medical Ltd. | Controlled tissue ablation techniques |
US10493275B2 (en) | 2009-04-22 | 2019-12-03 | Nevro Corp. | Spinal cord modulation for inducing paresthetic and anesthetic effects, and associated systems and methods |
US10631912B2 (en) | 2010-04-30 | 2020-04-28 | Medtronic Xomed, Inc. | Interface module for use with nerve monitoring and electrosurgery |
US10632310B2 (en) | 2013-10-09 | 2020-04-28 | GiMer Medical Co., Ltd. | Electronic stimulation device, method of treatment and electronic stimulation system |
US10639476B2 (en) | 2013-10-09 | 2020-05-05 | GiMer Medical Co., Ltd. | Electronic stimulation device, method of treatment and electronic stimulation system |
US10668285B2 (en) | 2008-12-05 | 2020-06-02 | Spr Therapeutics, Inc. | Systems and methods to place one or more leads in tissue to electrically stimulate nerves to treat pain |
US10694972B2 (en) | 2014-12-15 | 2020-06-30 | Virginia Tech Intellectual Properties, Inc. | Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment |
US10702326B2 (en) | 2011-07-15 | 2020-07-07 | Virginia Tech Intellectual Properties, Inc. | Device and method for electroporation based treatment of stenosis of a tubular body part |
US10722715B2 (en) | 2010-11-11 | 2020-07-28 | Spr Therapeutics, Inc. | Systems and methods for the treatment of pain through neural fiber stimulation |
US20200281646A1 (en) * | 2012-09-12 | 2020-09-10 | Relievant Medsystems, Inc. | Radiofrequency ablation of tissue within a vertebral body |
US10786669B2 (en) | 2006-10-02 | 2020-09-29 | Emkinetics, Inc. | Method and apparatus for transdermal stimulation over the palmar and plantar surfaces |
US10799701B2 (en) | 2016-03-30 | 2020-10-13 | Nevro Corp. | Systems and methods for identifying and treating patients with high-frequency electrical signals |
US10953225B2 (en) | 2017-11-07 | 2021-03-23 | Neurostim Oab, Inc. | Non-invasive nerve activator with adaptive circuit |
US11027123B2 (en) | 2008-12-05 | 2021-06-08 | Spr Therapeutics, Inc. | Systems and methods to place one or more leads in tissue to electrically stimulate nerves of passage to treat pain |
US11077301B2 (en) | 2015-02-21 | 2021-08-03 | NeurostimOAB, Inc. | Topical nerve stimulator and sensor for bladder control |
US20210244951A1 (en) * | 2019-03-08 | 2021-08-12 | Mayo Foundation For Medical Education And Research | Systems and methods for stellate ganglion stimulation and ablation |
US11103700B2 (en) | 2012-04-25 | 2021-08-31 | Medtronic, Inc. | Stimulation probe for robotic and laparoscopic surgery |
US20210290172A1 (en) * | 2018-05-07 | 2021-09-23 | Farapulse, Inc. | Systems, apparatuses, and methods for filtering high voltage noise induced by pulsed electric field ablation |
US11224742B2 (en) | 2006-10-02 | 2022-01-18 | Emkinetics, Inc. | Methods and devices for performing electrical stimulation to treat various conditions |
US11229789B2 (en) | 2013-05-30 | 2022-01-25 | Neurostim Oab, Inc. | Neuro activator with controller |
CN114007535A (en) * | 2019-04-18 | 2022-02-01 | 盖乐世公司 | Devices, systems, and methods for treating abnormal tissue |
US11254926B2 (en) | 2008-04-29 | 2022-02-22 | Virginia Tech Intellectual Properties, Inc. | Devices and methods for high frequency electroporation |
US11272979B2 (en) | 2008-04-29 | 2022-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
US11311329B2 (en) | 2018-03-13 | 2022-04-26 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for immunotherapy based treatments using non-thermal ablation techniques |
US11318310B1 (en) | 2015-10-26 | 2022-05-03 | Nevro Corp. | Neuromodulation for altering autonomic functions, and associated systems and methods |
US11382681B2 (en) | 2009-04-09 | 2022-07-12 | Virginia Tech Intellectual Properties, Inc. | Device and methods for delivery of high frequency electrical pulses for non-thermal ablation |
US11446504B1 (en) | 2016-05-27 | 2022-09-20 | Nevro Corp. | High frequency electromagnetic stimulation for modulating cells, including spontaneously active and quiescent cells, and associated systems and methods |
US11458311B2 (en) | 2019-06-26 | 2022-10-04 | Neurostim Technologies Llc | Non-invasive nerve activator patch with adaptive circuit |
US11471210B2 (en) | 2011-12-30 | 2022-10-18 | Relievant Medsystems, Inc. | Methods of denervating vertebral body using external energy source |
US11541235B2 (en) | 2016-08-26 | 2023-01-03 | Spr Therapeutics, Inc. | Devices and methods for delivery of electrical current for pain relief |
US11540973B2 (en) | 2016-10-21 | 2023-01-03 | Spr Therapeutics, Llc | Method and system of mechanical nerve stimulation for pain relief |
US11590352B2 (en) | 2019-01-29 | 2023-02-28 | Nevro Corp. | Ramped therapeutic signals for modulating inhibitory interneurons, and associated systems and methods |
US11596798B2 (en) | 2016-01-25 | 2023-03-07 | Nevro Corp | Treatment of congestive heart failure with electrical stimulation, and associated systems and methods |
US11602634B2 (en) | 2019-01-17 | 2023-03-14 | Nevro Corp. | Sensory threshold adaptation for neurological therapy screening and/or electrode selection, and associated systems and methods |
US11607537B2 (en) | 2017-12-05 | 2023-03-21 | Virginia Tech Intellectual Properties, Inc. | Method for treating neurological disorders, including tumors, with electroporation |
US11638603B2 (en) | 2009-04-09 | 2023-05-02 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
US11678932B2 (en) | 2016-05-18 | 2023-06-20 | Symap Medical (Suzhou) Limited | Electrode catheter with incremental advancement |
US11707629B2 (en) | 2009-05-28 | 2023-07-25 | Angiodynamics, Inc. | System and method for synchronizing energy delivery to the cardiac rhythm |
US11723710B2 (en) | 2016-11-17 | 2023-08-15 | Angiodynamics, Inc. | Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode |
US11730958B2 (en) | 2019-12-16 | 2023-08-22 | Neurostim Solutions, Llc | Non-invasive nerve activator with boosted charge delivery |
US11925405B2 (en) | 2018-03-13 | 2024-03-12 | Virginia Tech Intellectual Properties, Inc. | Treatment planning system for immunotherapy enhancement via non-thermal ablation |
US11931096B2 (en) | 2010-10-13 | 2024-03-19 | Angiodynamics, Inc. | System and method for electrically ablating tissue of a patient |
US11938317B2 (en) | 2017-12-26 | 2024-03-26 | Galvanize Therapeutics, Inc. | Optimization of energy delivery for various applications |
US11950835B2 (en) | 2019-06-28 | 2024-04-09 | Virginia Tech Intellectual Properties, Inc. | Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy |
Families Citing this family (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8774922B2 (en) | 2002-04-08 | 2014-07-08 | Medtronic Ardian Luxembourg S.A.R.L. | Catheter apparatuses having expandable balloons for renal neuromodulation and associated systems and methods |
US8145316B2 (en) | 2002-04-08 | 2012-03-27 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
US7162303B2 (en) | 2002-04-08 | 2007-01-09 | Ardian, Inc. | Renal nerve stimulation method and apparatus for treatment of patients |
US6978174B2 (en) * | 2002-04-08 | 2005-12-20 | Ardian, Inc. | Methods and devices for renal nerve blocking |
US8131371B2 (en) * | 2002-04-08 | 2012-03-06 | Ardian, Inc. | Methods and apparatus for monopolar renal neuromodulation |
US20070135875A1 (en) | 2002-04-08 | 2007-06-14 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
US8347891B2 (en) | 2002-04-08 | 2013-01-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen |
US8145317B2 (en) * | 2002-04-08 | 2012-03-27 | Ardian, Inc. | Methods for renal neuromodulation |
US8150519B2 (en) | 2002-04-08 | 2012-04-03 | Ardian, Inc. | Methods and apparatus for bilateral renal neuromodulation |
US7620451B2 (en) | 2005-12-29 | 2009-11-17 | Ardian, Inc. | Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach |
US20080213331A1 (en) | 2002-04-08 | 2008-09-04 | Ardian, Inc. | Methods and devices for renal nerve blocking |
US8175711B2 (en) * | 2002-04-08 | 2012-05-08 | Ardian, Inc. | Methods for treating a condition or disease associated with cardio-renal function |
US8774913B2 (en) * | 2002-04-08 | 2014-07-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for intravasculary-induced neuromodulation |
US7653438B2 (en) | 2002-04-08 | 2010-01-26 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
US9636174B2 (en) | 2002-04-08 | 2017-05-02 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
US20110207758A1 (en) * | 2003-04-08 | 2011-08-25 | Medtronic Vascular, Inc. | Methods for Therapeutic Renal Denervation |
US20140018880A1 (en) | 2002-04-08 | 2014-01-16 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for monopolar renal neuromodulation |
US9308043B2 (en) | 2002-04-08 | 2016-04-12 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for monopolar renal neuromodulation |
US20070129761A1 (en) | 2002-04-08 | 2007-06-07 | Ardian, Inc. | Methods for treating heart arrhythmia |
US9308044B2 (en) | 2002-04-08 | 2016-04-12 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
US7617005B2 (en) | 2002-04-08 | 2009-11-10 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
US7853333B2 (en) | 2002-04-08 | 2010-12-14 | Ardian, Inc. | Methods and apparatus for multi-vessel renal neuromodulation |
US7756583B2 (en) * | 2002-04-08 | 2010-07-13 | Ardian, Inc. | Methods and apparatus for intravascularly-induced neuromodulation |
US20040082859A1 (en) | 2002-07-01 | 2004-04-29 | Alan Schaer | Method and apparatus employing ultrasound energy to treat body sphincters |
US8361067B2 (en) | 2002-09-30 | 2013-01-29 | Relievant Medsystems, Inc. | Methods of therapeutically heating a vertebral body to treat back pain |
US6907884B2 (en) | 2002-09-30 | 2005-06-21 | Depay Acromed, Inc. | Method of straddling an intraosseous nerve |
US7258690B2 (en) | 2003-03-28 | 2007-08-21 | Relievant Medsystems, Inc. | Windowed thermal ablation probe |
US7937143B2 (en) * | 2004-11-02 | 2011-05-03 | Ardian, Inc. | Methods and apparatus for inducing controlled renal neuromodulation |
WO2007136566A2 (en) | 2006-05-19 | 2007-11-29 | Prorhythm, Inc. | Ablation device with optimized input power profile and method of using the same |
EP2465574B1 (en) * | 2006-06-28 | 2015-10-28 | Ardian, Inc. | Systems for thermally-induced renal neuromodulation |
US10028753B2 (en) | 2008-09-26 | 2018-07-24 | Relievant Medsystems, Inc. | Spine treatment kits |
EP2339972B1 (en) | 2008-09-26 | 2018-04-11 | Relievant Medsystems, Inc. | Systems for navigating an instrument through bone |
US8808345B2 (en) * | 2008-12-31 | 2014-08-19 | Medtronic Ardian Luxembourg S.A.R.L. | Handle assemblies for intravascular treatment devices and associated systems and methods |
US20100168739A1 (en) * | 2008-12-31 | 2010-07-01 | Ardian, Inc. | Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation |
US8652129B2 (en) | 2008-12-31 | 2014-02-18 | Medtronic Ardian Luxembourg S.A.R.L. | Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation |
EP2376011B1 (en) | 2009-01-09 | 2019-07-03 | ReCor Medical, Inc. | Apparatus for treatment of mitral valve insufficiency |
EP3132828B1 (en) | 2009-10-30 | 2017-10-11 | ReCor Medical, Inc. | Apparatus for treatment of hypertension through percutaneous ultrasound renal denervation |
US20110112400A1 (en) * | 2009-11-06 | 2011-05-12 | Ardian, Inc. | High intensity focused ultrasound catheter apparatuses, systems, and methods for renal neuromodulation |
US20110200171A1 (en) * | 2010-01-19 | 2011-08-18 | Ardian, Inc. | Methods and apparatus for renal neuromodulation via stereotactic radiotherapy |
JP5952195B2 (en) | 2010-01-26 | 2016-07-13 | エヴァンズ, マイケル エイ.EVANS, Michael A. | Method, apparatus and medicament for denervation |
US8870863B2 (en) | 2010-04-26 | 2014-10-28 | Medtronic Ardian Luxembourg S.A.R.L. | Catheter apparatuses, systems, and methods for renal neuromodulation |
JP6046041B2 (en) | 2010-10-25 | 2016-12-14 | メドトロニック アーディアン ルクセンブルク ソシエテ ア レスポンサビリテ リミテ | Devices, systems, and methods for neuromodulation therapy evaluation and feedback |
AU2011328926B2 (en) | 2010-11-16 | 2015-07-09 | Tva Medical, Inc. | Devices and methods for forming a fistula |
CA2843183A1 (en) | 2011-07-26 | 2013-01-31 | Amphora Medical, Inc. | Apparatus and methods to modulate pelvic nervous tissue |
WO2013067538A1 (en) | 2011-11-04 | 2013-05-10 | Nevro Corporation | Medical device communication and charding assemblies for use with implantable signal generators |
CN104125799A (en) * | 2011-11-07 | 2014-10-29 | 美敦力阿迪安卢森堡有限责任公司 | Endovascular nerve monitoring devices and associated systems and methods |
EP2788078B1 (en) | 2011-12-09 | 2020-09-02 | Metavention, Inc. | Therapeutic neuromodulation of the hepatic system |
JP2015511137A (en) | 2012-01-30 | 2015-04-16 | ビトロンユーエス, インコーポレイテッド | Tissue necrosis method and apparatus |
CA2865242A1 (en) | 2012-03-08 | 2013-09-12 | Medtronic Ardian Luxembourg S.A.R.L. | Biomarker sampling in the context of neuromodulation devices and associated systems and methods |
US9750568B2 (en) | 2012-03-08 | 2017-09-05 | Medtronic Ardian Luxembourg S.A.R.L. | Ovarian neuromodulation and associated systems and methods |
AU2013230893B2 (en) * | 2012-03-08 | 2015-12-03 | Medtronic Af Luxembourg S.A.R.L. | Neuromodulation and associated systems and methods for the management of pain |
JP6163549B2 (en) | 2012-06-30 | 2017-07-12 | ボストン サイエンティフィック ニューロモデュレイション コーポレイション | System for synthesizing low frequency sources for high frequency neuromodulation |
US9002459B2 (en) | 2012-09-19 | 2015-04-07 | Boston Scientific Neuromodulation Corporation | Method for selectively modulating neural elements in the dorsal horn |
US9333035B2 (en) | 2012-09-19 | 2016-05-10 | Denervx LLC | Cooled microwave denervation |
WO2014059351A1 (en) | 2012-10-11 | 2014-04-17 | Tva Medical, Inc. | Devices and methods for fistula formation |
US20140110296A1 (en) | 2012-10-19 | 2014-04-24 | Medtronic Ardian Luxembourg S.A.R.L. | Packaging for Catheter Treatment Devices and Associated Devices, Systems, and Methods |
EP3598952A3 (en) | 2012-11-05 | 2020-04-15 | Relievant Medsystems, Inc. | Systems and methods for creating curved paths through bone and modulating nerves within the bone |
WO2014070999A2 (en) | 2012-11-05 | 2014-05-08 | Landy Toth | Systems, methods, and devices for monitoring and treatment of tissues within and/or through a lumen wall |
AU2014218716B2 (en) | 2013-02-22 | 2017-10-19 | Boston Scientific Neuromodulation Corporation | Neurostimulation system having increased flexibility for creating complex pulse trains |
US10076384B2 (en) | 2013-03-08 | 2018-09-18 | Symple Surgical, Inc. | Balloon catheter apparatus with microwave emitter |
US9174053B2 (en) | 2013-03-08 | 2015-11-03 | Boston Scientific Neuromodulation Corporation | Neuromodulation using modulated pulse train |
CN106178294B (en) | 2013-03-14 | 2018-11-20 | 瑞蔻医药有限公司 | A kind of endovascular ablation system based on ultrasound |
JP6337080B2 (en) | 2013-03-14 | 2018-06-06 | リコール メディカル インコーポレイテッドReCor Medical, Inc. | Method for plating or coating an ultrasonic transducer |
US10821217B2 (en) | 2013-03-14 | 2020-11-03 | Tva Medical, Inc. | Fistula formation devices and methods therefor |
JP2016512758A (en) | 2013-03-15 | 2016-05-09 | ボストン サイエンティフィック ニューロモデュレイション コーポレイション | System and method for providing patients with subthreshold treatment |
US9180297B2 (en) | 2013-05-16 | 2015-11-10 | Boston Scientific Neuromodulation Corporation | System and method for spinal cord modulation to treat motor disorder without paresthesia |
US10029102B2 (en) | 2013-06-06 | 2018-07-24 | Boston Scientific Neuromodulation Corporation | System and method for delivering modulated sub-threshold therapy to a patient |
WO2014197564A1 (en) | 2013-06-06 | 2014-12-11 | Boston Scientific Neuromodulation Corporation | System for delivering sub-threshold and super-threshold therapy |
WO2014210373A1 (en) | 2013-06-28 | 2014-12-31 | Boston Scientific Neuromodulation Corporation | Electrode selection for sub-threshold modulation therapy |
EP3024540B1 (en) | 2013-07-26 | 2018-10-17 | Boston Scientific Neuromodulation Corporation | Systems of providing modulation therapy without perception |
US9724151B2 (en) | 2013-08-08 | 2017-08-08 | Relievant Medsystems, Inc. | Modulating nerves within bone using bone fasteners |
US10390881B2 (en) | 2013-10-25 | 2019-08-27 | Denervx LLC | Cooled microwave denervation catheter with insertion feature |
JP6137722B2 (en) | 2013-10-30 | 2017-05-31 | ボストン サイエンティフィック ニューロモデュレイション コーポレイション | Split control to avoid dorsal root stimulation |
US9333361B2 (en) | 2013-10-31 | 2016-05-10 | Boston Scientific Neuromodulation Corporation | System and method to automatically incorporate lead information from medical image into programmable user interface |
CN106029160B (en) | 2013-11-01 | 2019-03-15 | 波士顿科学神经调制公司 | For the system in midline delivering subthreshold value treatment |
US10010715B2 (en) | 2013-12-04 | 2018-07-03 | Boston Scientific Neuromodulation Corporation | Systems and methods for delivering therapy to the dorsal horn of a patient |
WO2015089411A2 (en) | 2013-12-12 | 2015-06-18 | Boston Scientific Neuromodulation Corporation | Systems and methods for programming a neuromodulation system |
CN103695311A (en) * | 2013-12-12 | 2014-04-02 | 新乡医学院 | Electrotransfection device and chick embryo optic tectum electrotransfection method using same |
US20150209107A1 (en) | 2014-01-24 | 2015-07-30 | Denervx LLC | Cooled microwave denervation catheter configuration |
WO2015120079A1 (en) | 2014-02-04 | 2015-08-13 | Amphora Medical, Inc. | Devices and methods for treating conditions caused by affarent nerve signals |
CN105980003A (en) | 2014-02-05 | 2016-09-28 | 波士顿科学神经调制公司 | System and method for delivering modulated sub-threshold therapy to a patient |
WO2015119773A1 (en) | 2014-02-05 | 2015-08-13 | Jordi Parramon | System and method for delivering modulated sub-threshold therapy to a patient |
US10510062B2 (en) * | 2014-03-07 | 2019-12-17 | First Data Corporation | Systems and methods for mobile device purchase flows |
WO2015138998A1 (en) | 2014-03-14 | 2015-09-17 | Tva Medical, Inc. | Fistula formation devices and methods therefor |
US10194979B1 (en) | 2014-03-28 | 2019-02-05 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for catheter-based renal neuromodulation |
US9980766B1 (en) | 2014-03-28 | 2018-05-29 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and systems for renal neuromodulation |
US10194980B1 (en) | 2014-03-28 | 2019-02-05 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for catheter-based renal neuromodulation |
US9409020B2 (en) | 2014-05-20 | 2016-08-09 | Nevro Corporation | Implanted pulse generators with reduced power consumption via signal strength/duration characteristics, and associated systems and methods |
CA2949962A1 (en) | 2014-05-23 | 2015-11-26 | Amphora Medical, Inc. | Methods and devices for treating pelvic conditions |
AU2015284047B2 (en) | 2014-07-03 | 2018-06-14 | Boston Scientific Neuromodulation Corporation | Neurostimulation system with flexible patterning and waveforms |
US9662495B2 (en) | 2014-07-24 | 2017-05-30 | Boston Scientific Neuromodulation Corporation | Enhanced dorsal horn stimulation using multiple electrical fields |
US10646666B2 (en) | 2014-08-27 | 2020-05-12 | Tva Medical, Inc. | Cryolipolysis devices and methods therefor |
CN106687173A (en) | 2014-09-15 | 2017-05-17 | 波士顿科学神经调制公司 | Graphical user interface for programming neurostimulation pulse patterns |
EP3197541B1 (en) | 2014-09-23 | 2020-11-04 | Boston Scientific Neuromodulation Corporation | Sub-perception modulation responsive to patient input |
EP3197537B1 (en) | 2014-09-23 | 2019-03-13 | Boston Scientific Neuromodulation Corporation | System for calibrating dorsal horn stimulation |
JP6564851B2 (en) | 2014-09-23 | 2019-08-21 | ボストン サイエンティフィック ニューロモデュレイション コーポレイション | Short pulse width stimulation |
EP3197551A1 (en) | 2014-09-23 | 2017-08-02 | Boston Scientific Neuromodulation Corporation | Perception calibration of neural tissue using field troll |
WO2016048951A1 (en) | 2014-09-23 | 2016-03-31 | Boston Scientific Neuromodulation Corporation | Neuromodulation specific to objective function of modulation field for targeted tissue |
JP6580678B2 (en) | 2014-09-23 | 2019-09-25 | ボストン サイエンティフィック ニューロモデュレイション コーポレイション | Neuromodulation using burst stimulation |
AU2015321576B2 (en) | 2014-09-23 | 2018-11-08 | Boston Scientific Neuromodulation Corporation | Systems and methods for receiving user-provided selection of electrode lists |
AU2015336218B2 (en) | 2014-10-22 | 2020-07-23 | Nevro Corp. | Systems and methods for extending the life of an implanted pulse generator battery |
AU2015343483B2 (en) | 2014-11-04 | 2018-03-01 | Boston Scientific Neuromodulation Corporation | Method and apparatus for programming complex neurostimulation patterns |
US10603040B1 (en) | 2015-02-09 | 2020-03-31 | Tva Medical, Inc. | Methods for treating hypertension and reducing blood pressure with formation of fistula |
EP3256206A1 (en) | 2015-02-09 | 2017-12-20 | Boston Scientific Neuromodulation Corporation | System for determining neurological position of epidural leads |
US9517344B1 (en) | 2015-03-13 | 2016-12-13 | Nevro Corporation | Systems and methods for selecting low-power, effective signal delivery parameters for an implanted pulse generator |
EP3302690B1 (en) | 2015-05-28 | 2019-09-25 | Boston Scientific Neuromodulation Corporation | Neuromodulation system using stochastically-modulated stimulation parameters |
AU2016297965B2 (en) | 2015-07-30 | 2019-04-04 | Boston Scientific Neuromodulation Corporation | User interface for custom patterned electrical stimulation |
US10835170B2 (en) * | 2015-08-11 | 2020-11-17 | Rhode Island Hospital | Methods for detecting neuronal oscillation in the spinal cord associated with pain and diseases or disorders of the nervous system |
US10603482B2 (en) * | 2015-09-23 | 2020-03-31 | Cala Health, Inc. | Systems and methods for peripheral nerve stimulation in the finger or hand to treat hand tremors |
CA3000878A1 (en) | 2015-10-07 | 2017-04-13 | Mayo Foundation For Medical Education And Research | Electroporation for obesity or diabetes treatment |
WO2017066187A1 (en) | 2015-10-15 | 2017-04-20 | Boston Scientific Neuromodulation Corporation | User interface for neurostimulation waveform composition |
US10675085B2 (en) | 2015-11-23 | 2020-06-09 | Boston Scientific Scimed, Inc. | Devices and methods for enhanced denervation procedures |
ES2904702T3 (en) | 2015-12-31 | 2022-04-05 | Nevro Corp | Controller for nerve stimulation circuit and associated systems and methods |
EP4299099A3 (en) | 2016-01-15 | 2024-04-03 | TVA Medical, Inc. | Devices for advancing a wire |
US10874422B2 (en) | 2016-01-15 | 2020-12-29 | Tva Medical, Inc. | Systems and methods for increasing blood flow |
US11026743B2 (en) | 2016-01-15 | 2021-06-08 | Tva Medical, Inc. | Devices and methods for forming a fistula |
JP6952699B2 (en) | 2016-01-21 | 2021-10-20 | カラ ヘルス, インコーポレイテッドCala Health, Inc. | Systems, methods and devices for peripheral nerve regulation to treat diseases associated with overactive bladder |
US10549099B2 (en) | 2016-04-29 | 2020-02-04 | University Of Utah Research Foundation | Electronic peripheral nerve stimulation |
US10524859B2 (en) | 2016-06-07 | 2020-01-07 | Metavention, Inc. | Therapeutic tissue modulation devices and methods |
CN114098949B (en) | 2016-06-27 | 2023-12-19 | 盖能适治疗股份有限公司 | Generator and catheter with electrode |
WO2018039117A1 (en) | 2016-08-22 | 2018-03-01 | Boston Scientific Neuromodulation Corporation | Neuromodulation system for providing paresthesia and analgesia and a system with leads and with electrodes |
MX2019003251A (en) | 2016-09-25 | 2019-07-18 | Tva Medical Inc | Vascular stent devices and methods. |
US10792495B2 (en) | 2016-12-01 | 2020-10-06 | Thimble Bioelectronics, Inc. | Neuromodulation device and method for use |
CN111511435A (en) | 2017-10-25 | 2020-08-07 | 艾品诺龙科技公司 | Systems and methods for delivering neuroregenerative therapy |
US10589089B2 (en) | 2017-10-25 | 2020-03-17 | Epineuron Technologies Inc. | Systems and methods for delivering neuroregenerative therapy |
CA3085452A1 (en) | 2017-12-13 | 2019-06-20 | Neuros Medical, Inc. | Nerve cuff deployment devices |
US11857778B2 (en) | 2018-01-17 | 2024-01-02 | Cala Health, Inc. | Systems and methods for treating inflammatory bowel disease through peripheral nerve stimulation |
CR20200357A (en) | 2018-01-30 | 2021-03-29 | Nevro Corp | Efficient use of an implantable pulse generator battery, and associated systems and methods |
EP3773876B1 (en) | 2018-04-09 | 2024-04-17 | Neuros Medical, Inc. | Apparatuses for setting an electrical dose |
US10933238B2 (en) | 2019-01-31 | 2021-03-02 | Nevro Corp. | Power control circuit for sterilized devices, and associated systems and methods |
CA3150339A1 (en) | 2019-09-12 | 2021-03-18 | Brian W. Donovan | Systems and methods for tissue modulation |
US11247043B2 (en) | 2019-10-01 | 2022-02-15 | Epineuron Technologies Inc. | Electrode interface devices for delivery of neuroregenerative therapy |
US11890468B1 (en) | 2019-10-03 | 2024-02-06 | Cala Health, Inc. | Neurostimulation systems with event pattern detection and classification |
US20210162210A1 (en) | 2019-12-03 | 2021-06-03 | Biosense Webster (Israel) Ltd. | Using reversible electroporation on cardiac tissue |
US11878172B2 (en) | 2020-02-11 | 2024-01-23 | Neuros Medical, Inc. | System and method for quantifying qualitative patient-reported data sets |
AU2021233980B2 (en) * | 2020-03-12 | 2024-01-04 | AEON Biopharma, Inc. | Neurotoxin compositions for use in treating cardiovascular disorders |
JP2024509644A (en) | 2021-04-07 | 2024-03-04 | ビーティーエル メディカル デベロップメント エー.エス. | Pulsed field ablation device and method |
WO2022221452A1 (en) * | 2021-04-13 | 2022-10-20 | Gate Science, Inc. | Systems, apparatuses and methods for pain management |
IL309432A (en) | 2021-07-06 | 2024-02-01 | Btl Medical Dev A S | Pulsed field ablation device and method |
Citations (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3911930A (en) * | 1974-03-01 | 1975-10-14 | Stimulation Tech | Method and structure of preventing and treating ileus, and reducing acute pain by electrical pulse stimulation |
US3991770A (en) * | 1974-01-24 | 1976-11-16 | Leveen Harry H | Method for treating benign and malignant tumors utilizing radio frequency, electromagnetic radiation |
US4141365A (en) * | 1977-02-24 | 1979-02-27 | The Johns Hopkins University | Epidural lead electrode and insertion needle |
US4154246A (en) * | 1977-07-25 | 1979-05-15 | Leveen Harry H | Field intensification in radio frequency thermotherapy |
US4573481A (en) * | 1984-06-25 | 1986-03-04 | Huntington Institute Of Applied Research | Implantable electrode array |
US5224492A (en) * | 1990-06-13 | 1993-07-06 | Omron Corporation | Thermotherapy apparatus |
US5284144A (en) * | 1989-11-22 | 1994-02-08 | The United States Of America As Represented By The Secretary Of The Dept. Of Health & Human Services | Apparatus for hyperthermia treatment of cancer |
US5620479A (en) * | 1992-11-13 | 1997-04-15 | The Regents Of The University Of California | Method and apparatus for thermal therapy of tumors |
US5649973A (en) * | 1992-11-13 | 1997-07-22 | Dornier Medical Systems, Inc. | Thermotherapy method with tissue cooling |
US5938690A (en) * | 1996-06-07 | 1999-08-17 | Advanced Neuromodulation Systems, Inc. | Pain management system and method |
US5983141A (en) * | 1996-06-27 | 1999-11-09 | Radionics, Inc. | Method and apparatus for altering neural tissue function |
US6161044A (en) * | 1998-11-23 | 2000-12-12 | Synaptic Corporation | Method and apparatus for treating chronic pain syndromes, tremor, dementia and related disorders and for inducing electroanesthesia using high frequency, high intensity transcutaneous electrical nerve stimulation |
US6246912B1 (en) * | 1996-06-27 | 2001-06-12 | Sherwood Services Ag | Modulated high frequency tissue modification |
US6302874B1 (en) * | 1998-07-13 | 2001-10-16 | Genetronics, Inc. | Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications |
US6326177B1 (en) * | 1999-08-04 | 2001-12-04 | Eastern Virginia Medical School Of The Medical College Of Hampton Roads | Method and apparatus for intracellular electro-manipulation |
US20020010501A1 (en) * | 2000-07-04 | 2002-01-24 | Yoshiaki Saito | Cancer thermotherapy |
US6516223B2 (en) * | 1997-08-01 | 2003-02-04 | Genetronics, Inc. | Apparatus for electroporation mediated delivery for drugs and genes |
US20030150372A1 (en) * | 2000-02-17 | 2003-08-14 | Yoram Palti | Method and apparatus for destroying dividing cells |
US20030216792A1 (en) * | 2002-04-08 | 2003-11-20 | Levin Howard R. | Renal nerve stimulation method and apparatus for treatment of patients |
US6654636B1 (en) * | 1998-07-13 | 2003-11-25 | Genetronics, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
US6678558B1 (en) * | 1999-03-25 | 2004-01-13 | Genetronics, Inc. | Method and apparatus for reducing electroporation-mediated muscle reaction and pain response |
US6678556B1 (en) * | 1998-07-13 | 2004-01-13 | Genetronics, Inc. | Electrical field therapy with reduced histopathological change in muscle |
US20040068296A1 (en) * | 2002-10-02 | 2004-04-08 | Standen Ltd. | Apparatus and method for treating a tumor or the like |
US20040068295A1 (en) * | 2002-10-02 | 2004-04-08 | Standen Limited | Apparatus for destroying dividing cells |
US20040147962A9 (en) * | 2001-01-18 | 2004-07-29 | Vladimir Kalina | Apparatus for inducing an immune response in cancer therapy |
US20040158288A1 (en) * | 2001-06-07 | 2004-08-12 | Yona Keisari | Method and apparatus for treating tumors using low strength electric fields |
US20040162590A1 (en) * | 2002-12-19 | 2004-08-19 | Whitehurst Todd K. | Fully implantable miniature neurostimulator for intercostal nerve stimulation as a therapy for angina pectoris |
US20040186532A1 (en) * | 2003-01-03 | 2004-09-23 | Tadlock Charles H. | System and method for stimulation of a person's brain stem |
US6847849B2 (en) * | 2000-11-15 | 2005-01-25 | Medtronic, Inc. | Minimally invasive apparatus for implanting a sacral stimulation lead |
US6862479B1 (en) * | 2000-08-30 | 2005-03-01 | Advanced Bionics Corporation | Spinal cord stimulation as a therapy for sexual dysfunction |
US6868289B2 (en) * | 2002-10-02 | 2005-03-15 | Standen Ltd. | Apparatus for treating a tumor or the like and articles incorporating the apparatus for treatment of the tumor |
US20050222623A1 (en) * | 2004-04-06 | 2005-10-06 | Oncostim Inc., A Minnesota Corporation | Partially implantable system for the electrical treatment of cancer |
US7146210B2 (en) * | 2000-02-17 | 2006-12-05 | Standen Ltd. | Apparatus and method for optimizing tumor treatment efficiency by electric fields |
Family Cites Families (198)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4618600A (en) | 1984-04-19 | 1986-10-21 | Biotechnology Research Associates, J.V. | Novel polypeptide diuretic/vasodilators |
US4602624A (en) | 1984-10-11 | 1986-07-29 | Case Western Reserve University | Implantable cuff, method of manufacture, and method of installation |
US4649936A (en) | 1984-10-11 | 1987-03-17 | Case Western Reserve University | Asymmetric single electrode cuff for generation of unidirectionally propagating action potentials for collision blocking |
US4709698A (en) | 1986-05-14 | 1987-12-01 | Thomas J. Fogarty | Heatable dilation catheter |
US4890623A (en) | 1988-03-14 | 1990-01-02 | C. R. Bard, Inc. | Biopotential sensing device and method for making |
US4955377A (en) | 1988-10-28 | 1990-09-11 | Lennox Charles D | Device and method for heating tissue in a patient's body |
WO1990007303A1 (en) | 1989-01-06 | 1990-07-12 | Angioplasty Systems, Inc. | Electrosurgical catheter for resolving atherosclerotic plaque |
US5779698A (en) | 1989-01-18 | 1998-07-14 | Applied Medical Resources Corporation | Angioplasty catheter system and method for making same |
US4976711A (en) | 1989-04-13 | 1990-12-11 | Everest Medical Corporation | Ablation catheter with selectively deployable electrodes |
US5425364A (en) | 1991-02-15 | 1995-06-20 | Cardiac Pathways Corporation | Flexible strip assembly without feedthrough holes and device utilizing the same |
ATE241938T1 (en) | 1991-11-08 | 2003-06-15 | Boston Scient Ltd | ABLATION ELECTRODE WITH INSULATED TEMPERATURE MEASUREMENT ELEMENT |
US5358514A (en) | 1991-12-18 | 1994-10-25 | Alfred E. Mann Foundation For Scientific Research | Implantable microdevice with self-attaching electrodes |
US5301683A (en) | 1991-12-23 | 1994-04-12 | Durkan John A | Diagnosing carpal tunnel syndrome |
US5697882A (en) | 1992-01-07 | 1997-12-16 | Arthrocare Corporation | System and method for electrosurgical cutting and ablation |
US5300068A (en) | 1992-04-21 | 1994-04-05 | St. Jude Medical, Inc. | Electrosurgical apparatus |
US5772590A (en) | 1992-06-30 | 1998-06-30 | Cordis Webster, Inc. | Cardiovascular catheter with laterally stable basket-shaped electrode array with puller wire |
US5484400A (en) | 1992-08-12 | 1996-01-16 | Vidamed, Inc. | Dual channel RF delivery system |
US5542916A (en) | 1992-08-12 | 1996-08-06 | Vidamed, Inc. | Dual-channel RF power delivery system |
WO1994007446A1 (en) | 1992-10-05 | 1994-04-14 | Boston Scientific Corporation | Device and method for heating tissue |
US5634899A (en) | 1993-08-20 | 1997-06-03 | Cortrak Medical, Inc. | Simultaneous cardiac pacing and local drug delivery method |
CA2109980A1 (en) | 1992-12-01 | 1994-06-02 | Mir A. Imran | Steerable catheter with adjustable bend location and/or radius and method |
US5256141A (en) | 1992-12-22 | 1993-10-26 | Nelson Gencheff | Biological material deployment method and apparatus |
US5860974A (en) | 1993-07-01 | 1999-01-19 | Boston Scientific Corporation | Heart ablation catheter with expandable electrode and method of coupling energy to an electrode on a catheter shaft |
CA2165829A1 (en) | 1993-07-01 | 1995-01-19 | John E. Abele | Imaging, electrical potential sensing, and ablation catheters |
US5571147A (en) | 1993-11-02 | 1996-11-05 | Sluijter; Menno E. | Thermal denervation of an intervertebral disc for relief of back pain |
US5599345A (en) | 1993-11-08 | 1997-02-04 | Zomed International, Inc. | RF treatment apparatus |
US6099524A (en) | 1994-01-28 | 2000-08-08 | Cardiac Pacemakers, Inc. | Electrophysiological mapping and ablation catheter and method |
US6405732B1 (en) | 1994-06-24 | 2002-06-18 | Curon Medical, Inc. | Method to treat gastric reflux via the detection and ablation of gastro-esophageal nerves and receptors |
US6009877A (en) | 1994-06-24 | 2000-01-04 | Edwards; Stuart D. | Method for treating a sphincter |
ATE308930T1 (en) | 1995-05-04 | 2005-11-15 | Sherwood Serv Ag | THERMO-SURGERY SYSTEM WITH COLD ELECTRIC TIP |
US6149620A (en) | 1995-11-22 | 2000-11-21 | Arthrocare Corporation | System and methods for electrosurgical tissue treatment in the presence of electrically conductive fluid |
US6322558B1 (en) | 1995-06-09 | 2001-11-27 | Engineering & Research Associates, Inc. | Apparatus and method for predicting ablation depth |
US5672174A (en) | 1995-08-15 | 1997-09-30 | Rita Medical Systems, Inc. | Multiple antenna ablation apparatus and method |
US5707400A (en) | 1995-09-19 | 1998-01-13 | Cyberonics, Inc. | Treating refractory hypertension by nerve stimulation |
US6283951B1 (en) | 1996-10-11 | 2001-09-04 | Transvascular, Inc. | Systems and methods for delivering drugs to selected locations within the body |
US5700282A (en) | 1995-10-13 | 1997-12-23 | Zabara; Jacob | Heart rhythm stabilization using a neurocybernetic prosthesis |
US6036687A (en) | 1996-03-05 | 2000-03-14 | Vnus Medical Technologies, Inc. | Method and apparatus for treating venous insufficiency |
US7269457B2 (en) * | 1996-04-30 | 2007-09-11 | Medtronic, Inc. | Method and system for vagal nerve stimulation with multi-site cardiac pacing |
US5944710A (en) | 1996-06-24 | 1999-08-31 | Genetronics, Inc. | Electroporation-mediated intravascular delivery |
US5893885A (en) | 1996-11-01 | 1999-04-13 | Cordis Webster, Inc. | Multi-electrode ablation catheter |
US6091995A (en) | 1996-11-08 | 2000-07-18 | Surx, Inc. | Devices, methods, and systems for shrinking tissues |
US5954719A (en) | 1996-12-11 | 1999-09-21 | Irvine Biomedical, Inc. | System for operating a RF ablation generator |
AU6156198A (en) | 1997-02-12 | 1998-08-26 | Oratec Interventions, Inc. | Concave probe for arthroscopic surgery |
US7027869B2 (en) | 1998-01-07 | 2006-04-11 | Asthmatx, Inc. | Method for treating an asthma attack |
US6024740A (en) | 1997-07-08 | 2000-02-15 | The Regents Of The University Of California | Circumferential ablation device assembly |
WO1999000060A1 (en) | 1997-06-26 | 1999-01-07 | Advanced Coronary Intervention | Electrosurgical catheter for resolving obstructions by radio frequency ablation |
USRE40279E1 (en) | 1997-06-26 | 2008-04-29 | Sherwood Services Ag | Method and system for neural tissue modification |
US6117101A (en) | 1997-07-08 | 2000-09-12 | The Regents Of The University Of California | Circumferential ablation device assembly |
US6869431B2 (en) | 1997-07-08 | 2005-03-22 | Atrionix, Inc. | Medical device with sensor cooperating with expandable member |
US6917834B2 (en) | 1997-12-03 | 2005-07-12 | Boston Scientific Scimed, Inc. | Devices and methods for creating lesions in endocardial and surrounding tissue to isolate focal arrhythmia substrates |
US6273886B1 (en) | 1998-02-19 | 2001-08-14 | Curon Medical, Inc. | Integrated tissue heating and cooling apparatus |
US6314325B1 (en) | 1998-04-07 | 2001-11-06 | William R. Fitz | Nerve hyperpolarization method and apparatus for pain relief |
US6219577B1 (en) | 1998-04-14 | 2001-04-17 | Global Vascular Concepts, Inc. | Iontophoresis, electroporation and combination catheters for local drug delivery to arteries and other body tissues |
US7198635B2 (en) | 2000-10-17 | 2007-04-03 | Asthmatx, Inc. | Modification of airways by application of energy |
US6292695B1 (en) | 1998-06-19 | 2001-09-18 | Wilton W. Webster, Jr. | Method and apparatus for transvascular treatment of tachycardia and fibrillation |
US6322559B1 (en) | 1998-07-06 | 2001-11-27 | Vnus Medical Technologies, Inc. | Electrode catheter having coil structure |
US6123702A (en) | 1998-09-10 | 2000-09-26 | Scimed Life Systems, Inc. | Systems and methods for controlling power in an electrosurgical probe |
US7313444B2 (en) | 1998-11-20 | 2007-12-25 | Pacesetter, Inc. | Self-anchoring coronary sinus lead |
ATE298536T1 (en) | 1999-03-09 | 2005-07-15 | Thermage Inc | DEVICE FOR TREATING TISSUE |
US6325797B1 (en) | 1999-04-05 | 2001-12-04 | Medtronic, Inc. | Ablation catheter and method for isolating a pulmonary vein |
US6939346B2 (en) | 1999-04-21 | 2005-09-06 | Oratec Interventions, Inc. | Method and apparatus for controlling a temperature-controlled probe |
WO2000066017A1 (en) | 1999-05-04 | 2000-11-09 | Curon Medical, Inc. | Electrodes for creating lesions in tissue regions at or near a sphincter |
US7171263B2 (en) | 1999-06-04 | 2007-01-30 | Impulse Dynamics Nv | Drug delivery device |
US7840278B1 (en) | 1999-06-25 | 2010-11-23 | Puskas John D | Devices and methods for vagus nerve stimulation |
JP2003510126A (en) | 1999-09-28 | 2003-03-18 | ノヴァシス メディカル インコーポレイテッド | Tissue treatment by application of energy and drugs |
US6711444B2 (en) | 1999-11-22 | 2004-03-23 | Scimed Life Systems, Inc. | Methods of deploying helical diagnostic and therapeutic element supporting structures within the body |
US6542781B1 (en) | 1999-11-22 | 2003-04-01 | Scimed Life Systems, Inc. | Loop structures for supporting diagnostic and therapeutic elements in contact with body tissue |
US6885888B2 (en) | 2000-01-20 | 2005-04-26 | The Cleveland Clinic Foundation | Electrical stimulation of the sympathetic nerve chain |
US6514226B1 (en) | 2000-02-10 | 2003-02-04 | Chf Solutions, Inc. | Method and apparatus for treatment of congestive heart failure by improving perfusion of the kidney |
US7565206B2 (en) | 2000-02-17 | 2009-07-21 | Standen Ltd. | Treating a tumor or the like with electric fields at different orientations |
US6770070B1 (en) | 2000-03-17 | 2004-08-03 | Rita Medical Systems, Inc. | Lung treatment apparatus and method |
ATE290827T1 (en) | 2000-06-13 | 2005-04-15 | Atrionix Inc | SURGICAL ABLATION PROBE FOR FORMING AN ANNUAL LESION |
US6546270B1 (en) | 2000-07-07 | 2003-04-08 | Biosense, Inc. | Multi-electrode catheter, system and method |
US6635054B2 (en) | 2000-07-13 | 2003-10-21 | Transurgical, Inc. | Thermal treatment methods and apparatus with focused energy application |
US6985774B2 (en) | 2000-09-27 | 2006-01-10 | Cvrx, Inc. | Stimulus regimens for cardiovascular reflex control |
US6850801B2 (en) | 2001-09-26 | 2005-02-01 | Cvrx, Inc. | Mapping methods for cardiovascular reflex control devices |
US6522926B1 (en) | 2000-09-27 | 2003-02-18 | Cvrx, Inc. | Devices and methods for cardiovascular reflex control |
US6845267B2 (en) | 2000-09-28 | 2005-01-18 | Advanced Bionics Corporation | Systems and methods for modulation of circulatory perfusion by electrical and/or drug stimulation |
US7306591B2 (en) | 2000-10-02 | 2007-12-11 | Novasys Medical, Inc. | Apparatus and methods for treating female urinary incontinence |
US7104987B2 (en) | 2000-10-17 | 2006-09-12 | Asthmatx, Inc. | Control system and process for application of energy to airway walls and other mediums |
US6616624B1 (en) | 2000-10-30 | 2003-09-09 | Cvrx, Inc. | Systems and method for controlling renovascular perfusion |
EP1363700A4 (en) | 2001-01-11 | 2005-11-09 | Rita Medical Systems Inc | Bone-treatment instrument and method |
US20020127144A1 (en) * | 2001-03-08 | 2002-09-12 | Mehta Shailesh P. | Device for analyzing particles and method of use |
US6972016B2 (en) | 2001-05-01 | 2005-12-06 | Cardima, Inc. | Helically shaped electrophysiology catheter |
US7160296B2 (en) | 2001-05-10 | 2007-01-09 | Rita Medical Systems, Inc. | Tissue ablation apparatus and method |
US20030050635A1 (en) | 2001-08-22 | 2003-03-13 | Csaba Truckai | Embolization systems and techniques for treating tumors |
US7778703B2 (en) | 2001-08-31 | 2010-08-17 | Bio Control Medical (B.C.M.) Ltd. | Selective nerve fiber stimulation for treating heart conditions |
US20030125790A1 (en) | 2001-12-27 | 2003-07-03 | Vitaly Fastovsky | Deployment device, system and method for medical implantation |
US6893436B2 (en) | 2002-01-03 | 2005-05-17 | Afx, Inc. | Ablation instrument having a flexible distal portion |
US6736835B2 (en) | 2002-03-21 | 2004-05-18 | Depuy Acromed, Inc. | Early intervention spinal treatment methods and devices for use therein |
WO2003082403A2 (en) | 2002-03-27 | 2003-10-09 | Cvrx, Inc. | Devices and methods for cardiovascular reflex control via coupled electrodes |
US8175711B2 (en) | 2002-04-08 | 2012-05-08 | Ardian, Inc. | Methods for treating a condition or disease associated with cardio-renal function |
US8347891B2 (en) | 2002-04-08 | 2013-01-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen |
US7617005B2 (en) | 2002-04-08 | 2009-11-10 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
US7620451B2 (en) | 2005-12-29 | 2009-11-17 | Ardian, Inc. | Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach |
US8131371B2 (en) | 2002-04-08 | 2012-03-06 | Ardian, Inc. | Methods and apparatus for monopolar renal neuromodulation |
US8145317B2 (en) | 2002-04-08 | 2012-03-27 | Ardian, Inc. | Methods for renal neuromodulation |
US20070129761A1 (en) | 2002-04-08 | 2007-06-07 | Ardian, Inc. | Methods for treating heart arrhythmia |
US20080213331A1 (en) | 2002-04-08 | 2008-09-04 | Ardian, Inc. | Methods and devices for renal nerve blocking |
US7653438B2 (en) | 2002-04-08 | 2010-01-26 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
US7756583B2 (en) | 2002-04-08 | 2010-07-13 | Ardian, Inc. | Methods and apparatus for intravascularly-induced neuromodulation |
US7853333B2 (en) | 2002-04-08 | 2010-12-14 | Ardian, Inc. | Methods and apparatus for multi-vessel renal neuromodulation |
US8145316B2 (en) | 2002-04-08 | 2012-03-27 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
US6978174B2 (en) | 2002-04-08 | 2005-12-20 | Ardian, Inc. | Methods and devices for renal nerve blocking |
US20070135875A1 (en) | 2002-04-08 | 2007-06-14 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
US8150519B2 (en) | 2002-04-08 | 2012-04-03 | Ardian, Inc. | Methods and apparatus for bilateral renal neuromodulation |
US8774913B2 (en) | 2002-04-08 | 2014-07-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for intravasculary-induced neuromodulation |
US8388604B2 (en) | 2003-02-21 | 2013-03-05 | Dtherapeutics, Llc | Devices, systems, and methods for removing contrast from luminal organs |
US6923808B2 (en) | 2003-02-24 | 2005-08-02 | Boston Scientific Scimed, Inc. | Probes having helical and loop shaped inflatable therapeutic elements |
WO2004078066A2 (en) | 2003-03-03 | 2004-09-16 | Sinus Rhythm Technologies, Inc. | Primary examiner |
US7221979B2 (en) | 2003-04-30 | 2007-05-22 | Medtronic, Inc. | Methods and apparatus for the regulation of hormone release |
JP4212949B2 (en) | 2003-05-06 | 2009-01-21 | 朝日インテック株式会社 | Chemical injection device |
US7149574B2 (en) | 2003-06-09 | 2006-12-12 | Palo Alto Investors | Treatment of conditions through electrical modulation of the autonomic nervous system |
EP3045136B1 (en) | 2003-09-12 | 2021-02-24 | Vessix Vascular, Inc. | Selectable eccentric remodeling and/or ablation of atherosclerotic material |
US7435248B2 (en) | 2003-09-26 | 2008-10-14 | Boston Scientific Scimed, Inc. | Medical probes for creating and diagnosing circumferential lesions within or around the ostium of a vessel |
US7416549B2 (en) | 2003-10-10 | 2008-08-26 | Boston Scientific Scimed, Inc. | Multi-zone bipolar ablation probe assembly |
US7231260B2 (en) | 2004-05-06 | 2007-06-12 | Boston Scientific Scimed, Inc. | Intravascular self-anchoring electrode body with arcuate springs, spring loops, or arms |
US20060085054A1 (en) | 2004-09-09 | 2006-04-20 | Zikorus Arthur W | Methods and apparatus for treatment of hollow anatomical structures |
US8920414B2 (en) | 2004-09-10 | 2014-12-30 | Vessix Vascular, Inc. | Tuned RF energy and electrical tissue characterization for selective treatment of target tissues |
US7524318B2 (en) | 2004-10-28 | 2009-04-28 | Boston Scientific Scimed, Inc. | Ablation probe with flared electrodes |
US20070083239A1 (en) | 2005-09-23 | 2007-04-12 | Denise Demarais | Methods and apparatus for inducing, monitoring and controlling renal neuromodulation |
US7937143B2 (en) | 2004-11-02 | 2011-05-03 | Ardian, Inc. | Methods and apparatus for inducing controlled renal neuromodulation |
US20060100618A1 (en) | 2004-11-08 | 2006-05-11 | Cardima, Inc. | System and method for performing ablation and other medical procedures using an electrode array with flex circuit |
CN101511292B (en) | 2005-03-28 | 2011-04-06 | 明诺医学有限公司 | Intraluminal electrical tissue characterization and tuned RF energy for selective treatment of atheroma and other target tissues |
US7390894B2 (en) | 2005-07-07 | 2008-06-24 | Mayo Foundation For Medical Education And Research | Glutathione S-transferase sequence variants |
US8834461B2 (en) | 2005-07-11 | 2014-09-16 | Medtronic Ablation Frontiers Llc | Low power tissue ablation system |
US20070021803A1 (en) | 2005-07-22 | 2007-01-25 | The Foundry Inc. | Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction |
US8140170B2 (en) | 2005-09-12 | 2012-03-20 | The Cleveland Clinic Foundation | Method and apparatus for renal neuromodulation |
US8712522B1 (en) | 2005-10-18 | 2014-04-29 | Cvrx, Inc. | System for setting programmable parameters for an implantable hypertension treatment device |
EP2465574B1 (en) | 2006-06-28 | 2015-10-28 | Ardian, Inc. | Systems for thermally-induced renal neuromodulation |
US20080119907A1 (en) | 2006-11-22 | 2008-05-22 | Cardiac Pacemakers, Inc. | Renal function modulation via application of electrical energy stimulation |
US8630704B2 (en) | 2007-06-25 | 2014-01-14 | Cardiac Pacemakers, Inc. | Neural stimulation with respiratory rhythm management |
US7848816B1 (en) | 2007-12-27 | 2010-12-07 | Pacesetter, Inc. | Acquiring nerve activity from carotid body and/or sinus |
US7949398B1 (en) | 2007-12-27 | 2011-05-24 | Pacesetter, Inc. | Acquiring nerve activity from carotid body and/or sinus |
US9204927B2 (en) | 2009-05-13 | 2015-12-08 | St. Jude Medical, Atrial Fibrillation Division, Inc. | System and method for presenting information representative of lesion formation in tissue during an ablation procedure |
US8585695B2 (en) | 2008-07-22 | 2013-11-19 | Hue-Teh Shih | Systems and methods for noncontact ablation |
US20100114244A1 (en) | 2008-10-31 | 2010-05-06 | Medtronic, Inc. | Electrical renal autonomic blockade |
US8652129B2 (en) | 2008-12-31 | 2014-02-18 | Medtronic Ardian Luxembourg S.A.R.L. | Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation |
US8808345B2 (en) | 2008-12-31 | 2014-08-19 | Medtronic Ardian Luxembourg S.A.R.L. | Handle assemblies for intravascular treatment devices and associated systems and methods |
US20100168739A1 (en) | 2008-12-31 | 2010-07-01 | Ardian, Inc. | Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation |
US8280477B2 (en) | 2009-07-29 | 2012-10-02 | Medtronic Cryocath Lp | Mono-phasic action potential electrogram recording catheter, and method |
US8568401B2 (en) | 2009-10-27 | 2013-10-29 | Covidien Lp | System for monitoring ablation size |
US20110112400A1 (en) | 2009-11-06 | 2011-05-12 | Ardian, Inc. | High intensity focused ultrasound catheter apparatuses, systems, and methods for renal neuromodulation |
US10631912B2 (en) | 2010-04-30 | 2020-04-28 | Medtronic Xomed, Inc. | Interface module for use with nerve monitoring and electrosurgery |
US20120123400A1 (en) | 2010-05-10 | 2012-05-17 | David Francischelli | Methods and devices for controlling energy during ablation |
US20120065506A1 (en) | 2010-09-10 | 2012-03-15 | Scott Smith | Mechanical, Electromechanical, and/or Elastographic Assessment for Renal Nerve Ablation |
US20120265198A1 (en) | 2010-11-19 | 2012-10-18 | Crow Loren M | Renal nerve detection and ablation apparatus and method |
US9023034B2 (en) | 2010-11-22 | 2015-05-05 | Boston Scientific Scimed, Inc. | Renal ablation electrode with force-activatable conduction apparatus |
US10016233B2 (en) | 2010-12-06 | 2018-07-10 | Biosense Webster (Israel) Ltd. | Treatment of atrial fibrillation using high-frequency pacing and ablation of renal nerves |
WO2012100211A2 (en) | 2011-01-20 | 2012-07-26 | Hansen Medical, Inc. | System and method for endoluminal and transluminal therapy |
US20120290053A1 (en) | 2011-05-11 | 2012-11-15 | St. Jude Medical, Inc. | Renal nerve stimulation lead, delivery system, and method |
US20120296232A1 (en) | 2011-05-18 | 2012-11-22 | St. Jude Medical, Inc. | Method and apparatus of assessing transvascular denervation |
EP2709517B1 (en) | 2011-05-18 | 2017-01-11 | St. Jude Medical, Inc. | Apparatus for assessing transvascular denervation |
US8909316B2 (en) | 2011-05-18 | 2014-12-09 | St. Jude Medical, Cardiology Division, Inc. | Apparatus and method of assessing transvascular denervation |
CN103813745B (en) | 2011-07-20 | 2016-06-29 | 波士顿科学西美德公司 | In order to visualize, be directed at and to melt transcutaneous device and the method for nerve |
US9022948B2 (en) | 2011-08-26 | 2015-05-05 | Symap Holding Limited | System and method for locating and identifying the functional nerves innervating the wall of arteries |
US8702619B2 (en) | 2011-08-26 | 2014-04-22 | Symap Holding Limited | Mapping sympathetic nerve distribution for renal ablation and catheters for same |
US9427579B2 (en) | 2011-09-29 | 2016-08-30 | Pacesetter, Inc. | System and method for performing renal denervation verification |
US20130116737A1 (en) | 2011-11-07 | 2013-05-09 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for Assessing Renal Neuromodulation Treatment and Associated Systems and Methods |
CN104125799A (en) | 2011-11-07 | 2014-10-29 | 美敦力阿迪安卢森堡有限责任公司 | Endovascular nerve monitoring devices and associated systems and methods |
US9119600B2 (en) | 2011-11-15 | 2015-09-01 | Boston Scientific Scimed, Inc. | Device and methods for renal nerve modulation monitoring |
WO2013096461A1 (en) | 2011-12-20 | 2013-06-27 | Cardiac Pacemakers, Inc. | Apparatus for monitoring and ablating nerves |
CN104135959A (en) | 2011-12-29 | 2014-11-05 | 波士顿科学西美德公司 | Device and methods for renal nerve modulation monitoring |
SG11201406006XA (en) | 2012-01-26 | 2014-11-27 | Autonomix Medical Inc | Controlled sympathectomy and micro-ablation systems and methods |
US20130218029A1 (en) | 2012-02-16 | 2013-08-22 | Pacesetter, Inc. | System and method for assessing renal artery nerve density |
CA2865242A1 (en) | 2012-03-08 | 2013-09-12 | Medtronic Ardian Luxembourg S.A.R.L. | Biomarker sampling in the context of neuromodulation devices and associated systems and methods |
US9439598B2 (en) | 2012-04-12 | 2016-09-13 | NeuroMedic, Inc. | Mapping and ablation of nerves within arteries and tissues |
US11357447B2 (en) | 2012-05-31 | 2022-06-14 | Sonivie Ltd. | Method and/or apparatus for measuring renal denervation effectiveness |
KR20150031324A (en) | 2012-07-05 | 2015-03-23 | 엠씨10, 인크 | Catheter device including flow sensing |
CN102743225B (en) | 2012-07-18 | 2014-04-02 | 深圳市惠泰医疗器械有限公司 | Radiofrequency ablation controlled electrode catheter for renal artery |
CN103284693B (en) | 2012-08-24 | 2014-12-24 | 苏州信迈医疗器械有限公司 | Instrument for locating and identifying nerves in vessel wall, and application method thereof |
TWI498101B (en) | 2012-08-30 | 2015-09-01 | Univ Nat Chiao Tung | Method of analyzing nerve fiber distribution and measuring standardized induced compound motion electric potential |
JP2014054430A (en) | 2012-09-13 | 2014-03-27 | Nippon Koden Corp | Catheter |
US10835305B2 (en) | 2012-10-10 | 2020-11-17 | Boston Scientific Scimed, Inc. | Renal nerve modulation devices and methods |
US9770593B2 (en) | 2012-11-05 | 2017-09-26 | Pythagoras Medical Ltd. | Patient selection using a transluminally-applied electric current |
CN107334525B (en) | 2012-11-05 | 2019-10-08 | 毕达哥拉斯医疗有限公司 | Controlled tissue ablation |
US20140316496A1 (en) | 2012-11-21 | 2014-10-23 | NeuroTronik IP Holding (Jersey) Limited | Intravascular Electrode Arrays for Neuromodulation |
JP6275158B2 (en) | 2012-12-10 | 2018-02-07 | コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. | Digital ruler and reticle for renal denervation |
WO2014091401A2 (en) | 2012-12-10 | 2014-06-19 | Perseus-Biomed Inc. | Dynamic denervation procedures and systems for the implementation thereof |
US10195467B2 (en) | 2013-02-21 | 2019-02-05 | Boston Scientific Scimed, Inc. | Ablation catheter system with wireless radio frequency temperature sensor |
US10028764B2 (en) | 2013-02-21 | 2018-07-24 | Boston Scientific Scimed, Inc. | Ablation catheter with wireless temperature sensor |
US20140249524A1 (en) | 2013-03-01 | 2014-09-04 | Boston Scientific Scimed, Inc. | System and method for performing renal nerve modulation |
US20140246465A1 (en) | 2013-03-03 | 2014-09-04 | Joan Darnell Peterson | Fish n stow |
AU2014249776B2 (en) | 2013-03-12 | 2017-04-20 | Boston Scientific Scimed, Inc. | Medical systems and methods for modulating nerves |
US9510902B2 (en) | 2013-03-13 | 2016-12-06 | St. Jude Medical, Cardiology Division, Inc. | Ablation catheters and systems including rotational monitoring means |
US8876813B2 (en) | 2013-03-14 | 2014-11-04 | St. Jude Medical, Inc. | Methods, systems, and apparatus for neural signal detection |
US9131982B2 (en) | 2013-03-14 | 2015-09-15 | St. Jude Medical, Cardiology Division, Inc. | Mediguide-enabled renal denervation system for ensuring wall contact and mapping lesion locations |
US9974477B2 (en) | 2013-03-15 | 2018-05-22 | St. Jude Medical, Cardiology Division, Inc. | Quantification of renal denervation via alterations in renal blood flow pre/post ablation |
US9297845B2 (en) | 2013-03-15 | 2016-03-29 | Boston Scientific Scimed, Inc. | Medical devices and methods for treatment of hypertension that utilize impedance compensation |
US20140276767A1 (en) | 2013-03-15 | 2014-09-18 | St. Jude Medical, Cardiology Division, Inc. | Ablation system, methods, and controllers |
EP2967728A1 (en) | 2013-03-15 | 2016-01-20 | St. Jude Medical, Cardiology Division, Inc. | Ablation system, methods, and controllers |
US9179973B2 (en) | 2013-03-15 | 2015-11-10 | St. Jude Medical, Cardiology Division, Inc. | Feedback systems and methods for renal denervation utilizing balloon catheter |
US9186212B2 (en) | 2013-03-15 | 2015-11-17 | St. Jude Medical, Cardiology Division, Inc. | Feedback systems and methods utilizing two or more sites along denervation catheter |
EP2991717A4 (en) | 2013-05-02 | 2016-12-07 | Douglas C Harrington | Devices and methods for detection and treatment of the aorticorenal ganglion |
CN105377168A (en) | 2013-05-08 | 2016-03-02 | 波士顿科学国际有限公司 | Systems and methods for temperature monitoring and control during an ablation procedure |
WO2015002787A1 (en) | 2013-07-01 | 2015-01-08 | Boston Scientific Scimed, Inc. | Medical devices for renal nerve ablation |
US20150025524A1 (en) | 2013-07-18 | 2015-01-22 | St. Jude Medical, Cardiology Division, Inc. | Renal denervation monitoring and feedback apparatus, system and method |
US20150223877A1 (en) | 2014-02-12 | 2015-08-13 | Perseus-Biomed Inc. | Methods and systems for treating nerve structures |
-
2006
- 2006-07-24 US US11/459,582 patent/US20070021803A1/en not_active Abandoned
-
2009
- 2009-09-25 US US12/567,521 patent/US8504147B2/en active Active
-
2013
- 2013-06-28 US US13/930,500 patent/US8676309B2/en not_active Expired - Fee Related
-
2014
- 2014-01-23 US US14/162,210 patent/US8989859B2/en active Active
-
2015
- 2015-02-04 US US14/613,971 patent/US9345538B2/en active Active
Patent Citations (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3991770A (en) * | 1974-01-24 | 1976-11-16 | Leveen Harry H | Method for treating benign and malignant tumors utilizing radio frequency, electromagnetic radiation |
US3911930A (en) * | 1974-03-01 | 1975-10-14 | Stimulation Tech | Method and structure of preventing and treating ileus, and reducing acute pain by electrical pulse stimulation |
US4141365A (en) * | 1977-02-24 | 1979-02-27 | The Johns Hopkins University | Epidural lead electrode and insertion needle |
US4154246A (en) * | 1977-07-25 | 1979-05-15 | Leveen Harry H | Field intensification in radio frequency thermotherapy |
US4573481A (en) * | 1984-06-25 | 1986-03-04 | Huntington Institute Of Applied Research | Implantable electrode array |
US5284144A (en) * | 1989-11-22 | 1994-02-08 | The United States Of America As Represented By The Secretary Of The Dept. Of Health & Human Services | Apparatus for hyperthermia treatment of cancer |
US5224492A (en) * | 1990-06-13 | 1993-07-06 | Omron Corporation | Thermotherapy apparatus |
US5620479A (en) * | 1992-11-13 | 1997-04-15 | The Regents Of The University Of California | Method and apparatus for thermal therapy of tumors |
US5649973A (en) * | 1992-11-13 | 1997-07-22 | Dornier Medical Systems, Inc. | Thermotherapy method with tissue cooling |
US5938690A (en) * | 1996-06-07 | 1999-08-17 | Advanced Neuromodulation Systems, Inc. | Pain management system and method |
US5983141A (en) * | 1996-06-27 | 1999-11-09 | Radionics, Inc. | Method and apparatus for altering neural tissue function |
US6246912B1 (en) * | 1996-06-27 | 2001-06-12 | Sherwood Services Ag | Modulated high frequency tissue modification |
US6516223B2 (en) * | 1997-08-01 | 2003-02-04 | Genetronics, Inc. | Apparatus for electroporation mediated delivery for drugs and genes |
US6678556B1 (en) * | 1998-07-13 | 2004-01-13 | Genetronics, Inc. | Electrical field therapy with reduced histopathological change in muscle |
US6697669B2 (en) * | 1998-07-13 | 2004-02-24 | Genetronics, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
US6302874B1 (en) * | 1998-07-13 | 2001-10-16 | Genetronics, Inc. | Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications |
US6654636B1 (en) * | 1998-07-13 | 2003-11-25 | Genetronics, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
US6161044A (en) * | 1998-11-23 | 2000-12-12 | Synaptic Corporation | Method and apparatus for treating chronic pain syndromes, tremor, dementia and related disorders and for inducing electroanesthesia using high frequency, high intensity transcutaneous electrical nerve stimulation |
US6678558B1 (en) * | 1999-03-25 | 2004-01-13 | Genetronics, Inc. | Method and apparatus for reducing electroporation-mediated muscle reaction and pain response |
US6326177B1 (en) * | 1999-08-04 | 2001-12-04 | Eastern Virginia Medical School Of The Medical College Of Hampton Roads | Method and apparatus for intracellular electro-manipulation |
US20030150372A1 (en) * | 2000-02-17 | 2003-08-14 | Yoram Palti | Method and apparatus for destroying dividing cells |
US7146210B2 (en) * | 2000-02-17 | 2006-12-05 | Standen Ltd. | Apparatus and method for optimizing tumor treatment efficiency by electric fields |
US20020010501A1 (en) * | 2000-07-04 | 2002-01-24 | Yoshiaki Saito | Cancer thermotherapy |
US6862479B1 (en) * | 2000-08-30 | 2005-03-01 | Advanced Bionics Corporation | Spinal cord stimulation as a therapy for sexual dysfunction |
US6847849B2 (en) * | 2000-11-15 | 2005-01-25 | Medtronic, Inc. | Minimally invasive apparatus for implanting a sacral stimulation lead |
US7160716B2 (en) * | 2001-01-18 | 2007-01-09 | Vladimir Kalina | Device for inducing an immune response in cancer therapy |
US20040147962A9 (en) * | 2001-01-18 | 2004-07-29 | Vladimir Kalina | Apparatus for inducing an immune response in cancer therapy |
US20040158288A1 (en) * | 2001-06-07 | 2004-08-12 | Yona Keisari | Method and apparatus for treating tumors using low strength electric fields |
US20030216792A1 (en) * | 2002-04-08 | 2003-11-20 | Levin Howard R. | Renal nerve stimulation method and apparatus for treatment of patients |
US7162303B2 (en) * | 2002-04-08 | 2007-01-09 | Ardian, Inc. | Renal nerve stimulation method and apparatus for treatment of patients |
US6868289B2 (en) * | 2002-10-02 | 2005-03-15 | Standen Ltd. | Apparatus for treating a tumor or the like and articles incorporating the apparatus for treatment of the tumor |
US7089054B2 (en) * | 2002-10-02 | 2006-08-08 | Standen Ltd. | Apparatus and method for treating a tumor or the like |
US20040068295A1 (en) * | 2002-10-02 | 2004-04-08 | Standen Limited | Apparatus for destroying dividing cells |
US20040068296A1 (en) * | 2002-10-02 | 2004-04-08 | Standen Ltd. | Apparatus and method for treating a tumor or the like |
US20040162590A1 (en) * | 2002-12-19 | 2004-08-19 | Whitehurst Todd K. | Fully implantable miniature neurostimulator for intercostal nerve stimulation as a therapy for angina pectoris |
US20040186532A1 (en) * | 2003-01-03 | 2004-09-23 | Tadlock Charles H. | System and method for stimulation of a person's brain stem |
US20050222623A1 (en) * | 2004-04-06 | 2005-10-06 | Oncostim Inc., A Minnesota Corporation | Partially implantable system for the electrical treatment of cancer |
Cited By (334)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7837719B2 (en) | 2002-05-09 | 2010-11-23 | Daemen College | Electrical stimulation unit and waterbath system |
US9339618B2 (en) | 2003-05-13 | 2016-05-17 | Holaira, Inc. | Method and apparatus for controlling narrowing of at least one airway |
US20060225742A1 (en) * | 2003-05-13 | 2006-10-12 | The Foundry, Inc. | Apparatus for treating asthma using neurotoxin |
US10953170B2 (en) | 2003-05-13 | 2021-03-23 | Nuvaira, Inc. | Apparatus for treating asthma using neurotoxin |
US8172827B2 (en) | 2003-05-13 | 2012-05-08 | Innovative Pulmonary Solutions, Inc. | Apparatus for treating asthma using neurotoxin |
US20060222667A1 (en) * | 2003-05-13 | 2006-10-05 | The Foundry, Inc. | Apparatus for treating asthma using neurotoxin |
US10894011B2 (en) | 2005-07-22 | 2021-01-19 | The Foundry, Llc | Systems and methods for delivery of a therapeutic agent |
US10052465B2 (en) | 2005-07-22 | 2018-08-21 | The Foundry, Llc | Methods and systems for toxin delivery to the nasal cavity |
US8636684B2 (en) | 2005-07-22 | 2014-01-28 | The Foundry Llc | Methods and systems for toxin delivery to the nasal cavity |
US8105817B2 (en) | 2005-07-22 | 2012-01-31 | The Foundry Llc | Methods and systems for toxin delivery to the nasal cavity |
US8989859B2 (en) | 2005-07-22 | 2015-03-24 | Medtronic Ardian Luxembourg S.A.R.L. | Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction |
US8961391B2 (en) | 2005-07-22 | 2015-02-24 | The Foundry, Llc | Systems and methods for delivery of a therapeutic agent |
US8133497B2 (en) | 2005-07-22 | 2012-03-13 | The Foundry, Llc | Systems and methods for delivery of a therapeutic agent |
US7655243B2 (en) | 2005-07-22 | 2010-02-02 | The Foundry, Llc | Methods and systems for toxin delivery to the nasal cavity |
US20100087775A1 (en) * | 2005-07-22 | 2010-04-08 | The Foundy, Llc | Methods and systems for toxin delivery to the nasal cavity |
US10022529B2 (en) | 2005-07-22 | 2018-07-17 | The Foundry, Llc | Systems and methods for delivery of a therapeutic agent |
US9700707B2 (en) | 2005-07-22 | 2017-07-11 | The Foundry, Llc | Methods and systems for toxin delivery to the nasal cavity |
US9345538B2 (en) | 2005-07-22 | 2016-05-24 | Medtronic Ardian Luxembourg S.A.R.L. | Systems and methods for neuromodulation for treatment of disorders associated with nerve conduction |
US10610675B2 (en) | 2005-07-22 | 2020-04-07 | The Foundry, Llc | Systems and methods for delivery of a therapeutic agent |
US11679077B2 (en) | 2005-07-22 | 2023-06-20 | The Foundry, Llc | Systems and methods for delivery of a therapeutic agent |
US8338164B2 (en) | 2005-07-22 | 2012-12-25 | The Foundry, Llc | Systems and methods for delivery of a therapeutic agent |
US10729897B2 (en) | 2005-07-22 | 2020-08-04 | The Foundry, Llc | Systems and methods for delivery of a therapeutic agent |
US9498283B2 (en) | 2005-07-22 | 2016-11-22 | The Foundry, Llc | Systems and methods for delivery of a therapeutic agent |
US11666526B2 (en) | 2005-07-22 | 2023-06-06 | The Foundry, Llc | Systems and methods for delivery of a therapeutic agent |
US20080154333A1 (en) * | 2005-09-26 | 2008-06-26 | Venturi Group, Llc | Neural blocking therapy |
US8798754B2 (en) | 2005-09-26 | 2014-08-05 | Venturi Group, Llc | Neural blocking therapy |
US9339641B2 (en) | 2006-01-17 | 2016-05-17 | Emkinetics, Inc. | Method and apparatus for transdermal stimulation over the palmar and plantar surfaces |
US9387338B2 (en) | 2006-01-17 | 2016-07-12 | Emkinetics, Inc. | Methods and devices for performing electrical stimulation to treat various conditions |
US9630004B2 (en) | 2006-01-17 | 2017-04-25 | Emkinetics, Inc. | Method and apparatus for transdermal stimulation over the palmar and plantar surfaces |
US9002477B2 (en) | 2006-01-17 | 2015-04-07 | Emkinetics, Inc. | Methods and devices for performing electrical stimulation to treat various conditions |
US9757584B2 (en) | 2006-01-17 | 2017-09-12 | Emkinetics, Inc. | Methods and devices for performing electrical stimulation to treat various conditions |
US9511210B2 (en) | 2006-05-19 | 2016-12-06 | The Foundry, Llc | Apparatus for toxin delivery to the nasal cavity |
US20070267011A1 (en) * | 2006-05-19 | 2007-11-22 | The Foundry Inc. | Apparatus for toxin delivery to the nasal cavity |
WO2007137235A2 (en) | 2006-05-19 | 2007-11-29 | The Foundry Inc. | Apparatus, methods and systems for toxin delivery to the nasal cavity |
US20100160712A1 (en) * | 2006-10-02 | 2010-06-24 | Daniel Rogers Burnett | Method and apparatus for magnetic induction therapy |
US20090227831A1 (en) * | 2006-10-02 | 2009-09-10 | Burnett Daniel R | Method and apparatus for magnetic induction therapy |
US20090227829A1 (en) * | 2006-10-02 | 2009-09-10 | Burnett Daniel R | Method and apparatus for magnetic induction therapy |
US11844943B2 (en) | 2006-10-02 | 2023-12-19 | Emkinetics, Inc. | Method and apparatus for transdermal stimulation over the palmar and plantar surfaces |
US11224742B2 (en) | 2006-10-02 | 2022-01-18 | Emkinetics, Inc. | Methods and devices for performing electrical stimulation to treat various conditions |
US8435166B2 (en) | 2006-10-02 | 2013-05-07 | Emkinetics, Inc. | Method and apparatus for magnetic induction therapy |
US8430805B2 (en) | 2006-10-02 | 2013-04-30 | Emkinetics, Inc. | Method and apparatus for magnetic induction therapy |
US10786669B2 (en) | 2006-10-02 | 2020-09-29 | Emkinetics, Inc. | Method and apparatus for transdermal stimulation over the palmar and plantar surfaces |
US20090234179A1 (en) * | 2006-10-02 | 2009-09-17 | Burnett Daniel R | Method and apparatus for magnetic induction therapy |
US20100204538A1 (en) * | 2006-10-02 | 2010-08-12 | Daniel Rogers Burnett | Method and apparatus for magnetic induction therapy |
US20080306325A1 (en) * | 2006-10-02 | 2008-12-11 | Emkinetics | Method and apparatus for magnetic induction therapy |
US11247053B2 (en) | 2006-10-02 | 2022-02-15 | Emkinetics, Inc. | Method and apparatus for transdermal stimulation over the palmar and plantar surfaces |
US20100168501A1 (en) * | 2006-10-02 | 2010-07-01 | Daniel Rogers Burnett | Method and apparatus for magnetic induction therapy |
US11628300B2 (en) | 2006-10-02 | 2023-04-18 | Emkinetics, Inc. | Method and apparatus for transdermal stimulation over the palmar and plantar surfaces |
US9005102B2 (en) | 2006-10-02 | 2015-04-14 | Emkinetics, Inc. | Method and apparatus for electrical stimulation therapy |
US11058336B2 (en) | 2007-05-08 | 2021-07-13 | Propep, Llc | System and method for laparoscopic nerve detection |
US20080281313A1 (en) * | 2007-05-08 | 2008-11-13 | Randy Fagin | System and Method for Laparoscopic Nerve Detection |
US11918362B2 (en) | 2007-05-08 | 2024-03-05 | Propep, Llc | System and method for laparoscopic nerve detection |
US8083685B2 (en) * | 2007-05-08 | 2011-12-27 | Propep, Llc | System and method for laparoscopic nerve detection |
US20090204173A1 (en) * | 2007-11-05 | 2009-08-13 | Zi-Ping Fang | Multi-Frequency Neural Treatments and Associated Systems and Methods |
US8774926B2 (en) | 2007-11-05 | 2014-07-08 | Nevro Corporation | Multi-frequency neural treatments and associated systems and methods |
US8768472B2 (en) | 2007-11-05 | 2014-07-01 | Nevro Corporation | Multi-frequency neural treatments and associated systems and methods |
US8731672B2 (en) | 2008-02-15 | 2014-05-20 | Holaira, Inc. | System and method for bronchial dilation |
US9125643B2 (en) | 2008-02-15 | 2015-09-08 | Holaira, Inc. | System and method for bronchial dilation |
US11058879B2 (en) | 2008-02-15 | 2021-07-13 | Nuvaira, Inc. | System and method for bronchial dilation |
US8483831B1 (en) | 2008-02-15 | 2013-07-09 | Holaira, Inc. | System and method for bronchial dilation |
US8489192B1 (en) | 2008-02-15 | 2013-07-16 | Holaira, Inc. | System and method for bronchial dilation |
US11453873B2 (en) | 2008-04-29 | 2022-09-27 | Virginia Tech Intellectual Properties, Inc. | Methods for delivery of biphasic electrical pulses for non-thermal ablation |
US10272178B2 (en) | 2008-04-29 | 2019-04-30 | Virginia Tech Intellectual Properties Inc. | Methods for blood-brain barrier disruption using electrical energy |
US11254926B2 (en) | 2008-04-29 | 2022-02-22 | Virginia Tech Intellectual Properties, Inc. | Devices and methods for high frequency electroporation |
US11272979B2 (en) | 2008-04-29 | 2022-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
US9198733B2 (en) | 2008-04-29 | 2015-12-01 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for electroporation-based therapies |
US8465484B2 (en) | 2008-04-29 | 2013-06-18 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation using nanoparticles |
US10828085B2 (en) | 2008-04-29 | 2020-11-10 | Virginia Tech Intellectual Properties, Inc. | Immunotherapeutic methods using irreversible electroporation |
US9283051B2 (en) | 2008-04-29 | 2016-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating a treatment volume for administering electrical-energy based therapies |
US11607271B2 (en) | 2008-04-29 | 2023-03-21 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating a treatment volume for administering electrical-energy based therapies |
US10959772B2 (en) | 2008-04-29 | 2021-03-30 | Virginia Tech Intellectual Properties, Inc. | Blood-brain barrier disruption using electrical energy |
US11655466B2 (en) | 2008-04-29 | 2023-05-23 | Virginia Tech Intellectual Properties, Inc. | Methods of reducing adverse effects of non-thermal ablation |
US10154874B2 (en) | 2008-04-29 | 2018-12-18 | Virginia Tech Intellectual Properties, Inc. | Immunotherapeutic methods using irreversible electroporation |
US10238447B2 (en) | 2008-04-29 | 2019-03-26 | Virginia Tech Intellectual Properties, Inc. | System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress |
US10245105B2 (en) | 2008-04-29 | 2019-04-02 | Virginia Tech Intellectual Properties, Inc. | Electroporation with cooling to treat tissue |
US11737810B2 (en) | 2008-04-29 | 2023-08-29 | Virginia Tech Intellectual Properties, Inc. | Immunotherapeutic methods using electroporation |
US10245098B2 (en) | 2008-04-29 | 2019-04-02 | Virginia Tech Intellectual Properties, Inc. | Acute blood-brain barrier disruption using electrical energy based therapy |
US20100331758A1 (en) * | 2008-04-29 | 2010-12-30 | Davalos Rafael V | Irreversible electroporation using nanoparticles |
US10286108B2 (en) | 2008-04-29 | 2019-05-14 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation to create tissue scaffolds |
US9867652B2 (en) | 2008-04-29 | 2018-01-16 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds |
US8992517B2 (en) | 2008-04-29 | 2015-03-31 | Virginia Tech Intellectual Properties Inc. | Irreversible electroporation to treat aberrant cell masses |
US10828086B2 (en) | 2008-04-29 | 2020-11-10 | Virginia Tech Intellectual Properties, Inc. | Immunotherapeutic methods using irreversible electroporation |
US8814860B2 (en) | 2008-04-29 | 2014-08-26 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation using nanoparticles |
US20090269317A1 (en) * | 2008-04-29 | 2009-10-29 | Davalos Rafael V | Irreversible electroporation to create tissue scaffolds |
US11890046B2 (en) | 2008-04-29 | 2024-02-06 | Virginia Tech Intellectual Properties, Inc. | System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress |
US10117707B2 (en) | 2008-04-29 | 2018-11-06 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
US11952568B2 (en) | 2008-04-29 | 2024-04-09 | Virginia Tech Intellectual Properties, Inc. | Device and methods for delivery of biphasic electrical pulses for non-thermal ablation |
US9598691B2 (en) | 2008-04-29 | 2017-03-21 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation to create tissue scaffolds |
US10470822B2 (en) | 2008-04-29 | 2019-11-12 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating a treatment volume for administering electrical-energy based therapies |
US10537379B2 (en) | 2008-04-29 | 2020-01-21 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds |
US8961507B2 (en) | 2008-05-09 | 2015-02-24 | Holaira, Inc. | Systems, assemblies, and methods for treating a bronchial tree |
US11937868B2 (en) | 2008-05-09 | 2024-03-26 | Nuvaira, Inc. | Systems, assemblies, and methods for treating a bronchial tree |
US8821489B2 (en) | 2008-05-09 | 2014-09-02 | Holaira, Inc. | Systems, assemblies, and methods for treating a bronchial tree |
US10149714B2 (en) | 2008-05-09 | 2018-12-11 | Nuvaira, Inc. | Systems, assemblies, and methods for treating a bronchial tree |
US8808280B2 (en) | 2008-05-09 | 2014-08-19 | Holaira, Inc. | Systems, assemblies, and methods for treating a bronchial tree |
US8088127B2 (en) | 2008-05-09 | 2012-01-03 | Innovative Pulmonary Solutions, Inc. | Systems, assemblies, and methods for treating a bronchial tree |
US8226638B2 (en) | 2008-05-09 | 2012-07-24 | Innovative Pulmonary Solutions, Inc. | Systems, assemblies, and methods for treating a bronchial tree |
US9668809B2 (en) | 2008-05-09 | 2017-06-06 | Holaira, Inc. | Systems, assemblies, and methods for treating a bronchial tree |
US20090306644A1 (en) * | 2008-05-09 | 2009-12-10 | Innovative Pulmonary Solutions, Inc. | Systems, assemblies, and methods for treating a bronchial tree |
US8961508B2 (en) | 2008-05-09 | 2015-02-24 | Holaira, Inc. | Systems, assemblies, and methods for treating a bronchial tree |
US20110307029A1 (en) * | 2008-08-06 | 2011-12-15 | Cerephex Corporation | Brain stimulation methods for treating central sensitivity |
US10022516B2 (en) * | 2008-08-14 | 2018-07-17 | The Cleveland Clinic Foundation | Apparatus and method for treating a neuromuscular defect |
US20100143413A1 (en) * | 2008-08-14 | 2010-06-10 | The Cleveland Clinic Foundation | Apparatus and method for treating a neuromuscular defect |
US20160166799A1 (en) * | 2008-08-14 | 2016-06-16 | The Cleveland Clinic Foundation | Apparatus and method for treating a neuromuscular defect |
US8512715B2 (en) * | 2008-08-14 | 2013-08-20 | The Cleveland Clinic Foundation | Apparatus and method for treating a neuromuscular defect |
US11771891B2 (en) | 2008-12-05 | 2023-10-03 | Spr Therapeutics, Inc. | Systems and methods to place one or more leads in tissue to electrically stimulate nerves of passage to treat pain |
AU2009322895B2 (en) * | 2008-12-05 | 2015-09-24 | Spr Therapeutics, Inc. | Systems and methods to place one or more leads in tissue for providing functional and/or therapeutic stimulation |
US20100152808A1 (en) * | 2008-12-05 | 2010-06-17 | Ndi Medical, Llc | Systems and methods to place one or more leads in tissue to electrically stimulate nerves of passage to treat pain |
US8954153B2 (en) * | 2008-12-05 | 2015-02-10 | Ndi Medical, Llc | Systems and methods to place one or more leads in tissue to electrically stimulate nerves of passage to treat pain |
US11420057B2 (en) | 2008-12-05 | 2022-08-23 | Spr Therapeutics, Inc. | Systems and methods to place one or more leads in tissue for providing functional and/or therapeutic stimulation |
WO2010065146A1 (en) * | 2008-12-05 | 2010-06-10 | Ndi Medical, Llc | Systems and methods to place one or more leads in tissue to electrically stimulate nerves of passage to treat pain |
WO2010065143A1 (en) * | 2008-12-05 | 2010-06-10 | Ndi Medical, Llc | Systems and methods to place one or more leads in tissue for providing functional and/or therapeutic stimulation |
US10426959B2 (en) | 2008-12-05 | 2019-10-01 | Spr Therapeutics, Inc. | Systems and methods to place one or more leads in tissue for providing functional and/or therapeutic stimulation |
AU2009322898B2 (en) * | 2008-12-05 | 2015-03-12 | Spr Therapeutics, Inc. | Systems and methods to place one or more leads in tissue to electrically stimulate nerves of passage to treat pain |
US10668285B2 (en) | 2008-12-05 | 2020-06-02 | Spr Therapeutics, Inc. | Systems and methods to place one or more leads in tissue to electrically stimulate nerves to treat pain |
US20100152809A1 (en) * | 2008-12-05 | 2010-06-17 | Ndi Medical, Llc | Systems and methods to place one or more leads in tissue for providing functional and/or therapeutic stimulation |
US11311727B2 (en) | 2008-12-05 | 2022-04-26 | Spr Therapeutics, Inc. | Systems and methods to place one or more leads in tissue to electrically stimulate nerves to treat pain |
US9884189B2 (en) | 2008-12-05 | 2018-02-06 | Spr Therapeutics, Inc. | Systems and methods to place one or more leads in tissue for providing functional and/or therapeutic stimulation |
US11027123B2 (en) | 2008-12-05 | 2021-06-08 | Spr Therapeutics, Inc. | Systems and methods to place one or more leads in tissue to electrically stimulate nerves of passage to treat pain |
US8509906B2 (en) | 2009-01-29 | 2013-08-13 | Nevro Corporation | Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions |
US10918867B2 (en) | 2009-01-29 | 2021-02-16 | Nevro Corp. | Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions |
US20100191307A1 (en) * | 2009-01-29 | 2010-07-29 | Zi-Ping Fang | Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions |
US8849410B2 (en) | 2009-01-29 | 2014-09-30 | Nevro Corporation | Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions |
US10179241B2 (en) | 2009-01-29 | 2019-01-15 | Nevro Corp. | Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions |
US10173065B2 (en) | 2009-01-29 | 2019-01-08 | Nevro Corp. | Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions |
US8255057B2 (en) | 2009-01-29 | 2012-08-28 | Nevro Corporation | Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions |
US11883670B2 (en) | 2009-01-29 | 2024-01-30 | Nevro Corp. | Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions |
US9403013B2 (en) | 2009-01-29 | 2016-08-02 | Nevro Corporation | Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions |
US10448989B2 (en) | 2009-04-09 | 2019-10-22 | Virginia Tech Intellectual Properties, Inc. | High-frequency electroporation for cancer therapy |
WO2010118387A1 (en) * | 2009-04-09 | 2010-10-14 | Virginia Tech Intellectual Properties, Inc. | Integration of very short electric pulses for minimally to noninvasive electroporation |
US20100261994A1 (en) * | 2009-04-09 | 2010-10-14 | Rafael Davalos | Integration of very short electric pulses for minimally to noninvasive electroporation |
US11638603B2 (en) | 2009-04-09 | 2023-05-02 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
US11382681B2 (en) | 2009-04-09 | 2022-07-12 | Virginia Tech Intellectual Properties, Inc. | Device and methods for delivery of high frequency electrical pulses for non-thermal ablation |
US10292755B2 (en) | 2009-04-09 | 2019-05-21 | Virginia Tech Intellectual Properties, Inc. | High frequency electroporation for cancer therapy |
US8926606B2 (en) | 2009-04-09 | 2015-01-06 | Virginia Tech Intellectual Properties, Inc. | Integration of very short electric pulses for minimally to noninvasive electroporation |
KR20200137038A (en) * | 2009-04-16 | 2020-12-08 | 이노비오 파마수티컬즈, 인크. | Contactless electropermeabilization electrode and method |
KR102560518B1 (en) * | 2009-04-16 | 2023-07-28 | 이노비오 파마수티컬즈, 인크. | Device comprising contactless electropermeabilization electrode |
US10232173B2 (en) | 2009-04-16 | 2019-03-19 | Vgx Pharmaceuticals, Llc | Contactless electropermeabilization electrode and method |
KR102309963B1 (en) * | 2009-04-16 | 2021-10-08 | 이노비오 파마수티컬즈, 인크. | Contactless electropermeabilization electrode and method |
KR20220045067A (en) * | 2009-04-16 | 2022-04-12 | 이노비오 파마수티컬즈, 인크. | Contactless electropermeabilization electrode and method |
KR102422470B1 (en) * | 2009-04-16 | 2022-07-20 | 이노비오 파마수티컬즈, 인크. | Contactless electropermeabilization electrode and method |
KR20170136021A (en) * | 2009-04-16 | 2017-12-08 | 이노비오 파마수티컬즈, 인크. | Contactless electropermeabilization electrode and method |
US8886328B2 (en) | 2009-04-22 | 2014-11-11 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US8886327B2 (en) | 2009-04-22 | 2014-11-11 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US20100274317A1 (en) * | 2009-04-22 | 2010-10-28 | Jon Parker | Devices for controlling high frequency spinal cord modulation for inhibiting pain, and associated systems and methods, including simplified contact selection |
US9327125B2 (en) | 2009-04-22 | 2016-05-03 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US8874217B2 (en) | 2009-04-22 | 2014-10-28 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US9480842B2 (en) | 2009-04-22 | 2016-11-01 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US20100274318A1 (en) * | 2009-04-22 | 2010-10-28 | Walker Andre B | Devices for controlling high frequency spinal cord modulation for inhibiting pain, and associated systems and methods, including simplified program selection |
US10603494B2 (en) | 2009-04-22 | 2020-03-31 | Nevro Corp. | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US20100274314A1 (en) * | 2009-04-22 | 2010-10-28 | Konstantinos Alataris | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US9592388B2 (en) | 2009-04-22 | 2017-03-14 | Nevro Corp. | Devices for controlling high frequency spinal cord modulation for inhibiting pain, and associated systems and methods, including simplified contact selection |
US20100274316A1 (en) * | 2009-04-22 | 2010-10-28 | Konstantinos Alataris | Devices for controlling high frequency spinal cord modulation for inhibiting pain, and associated systems and methods, including simplified controllers |
US8862239B2 (en) | 2009-04-22 | 2014-10-14 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US8838248B2 (en) | 2009-04-22 | 2014-09-16 | Nevro Corporation | Devices for controlling high frequency spinal cord modulation for inhibiting pain, and associated systems and methods, including simplified program selection |
US8874221B2 (en) | 2009-04-22 | 2014-10-28 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US11786731B2 (en) | 2009-04-22 | 2023-10-17 | Nevro Corp. | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US10493275B2 (en) | 2009-04-22 | 2019-12-03 | Nevro Corp. | Spinal cord modulation for inducing paresthetic and anesthetic effects, and associated systems and methods |
US8792988B2 (en) | 2009-04-22 | 2014-07-29 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US8874222B2 (en) | 2009-04-22 | 2014-10-28 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US11759638B2 (en) | 2009-04-22 | 2023-09-19 | Nevro Corp. | Spinal cord modulation for inducing paresthetic and anesthetic effects, and associated systems and methods |
US10471258B2 (en) | 2009-04-22 | 2019-11-12 | Nevro Corp. | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US8170675B2 (en) | 2009-04-22 | 2012-05-01 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US10463857B2 (en) | 2009-04-22 | 2019-11-05 | Nevro Corp. | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US8509905B2 (en) | 2009-04-22 | 2013-08-13 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US9327127B2 (en) | 2009-04-22 | 2016-05-03 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US8880177B2 (en) | 2009-04-22 | 2014-11-04 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US10413729B2 (en) | 2009-04-22 | 2019-09-17 | Nevro Corp. | Devices for controlling high frequency spinal cord modulation for inhibiting pain, and associated systems and methods, including simplified contact selection |
US8209021B2 (en) | 2009-04-22 | 2012-06-26 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US8355792B2 (en) | 2009-04-22 | 2013-01-15 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US8359102B2 (en) | 2009-04-22 | 2013-01-22 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US8718782B2 (en) | 2009-04-22 | 2014-05-06 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US8718781B2 (en) | 2009-04-22 | 2014-05-06 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US8359103B2 (en) | 2009-04-22 | 2013-01-22 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US9248293B2 (en) | 2009-04-22 | 2016-02-02 | Nevro Corporation | Devices for controlling high frequency spinal cord modulation for inhibiting pain, and associated systems and methods, including simplified program selection |
US8396559B2 (en) | 2009-04-22 | 2013-03-12 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US8712533B2 (en) | 2009-04-22 | 2014-04-29 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US9327126B2 (en) | 2009-04-22 | 2016-05-03 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US8886326B2 (en) | 2009-04-22 | 2014-11-11 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US9387327B2 (en) | 2009-04-22 | 2016-07-12 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US8423147B2 (en) | 2009-04-22 | 2013-04-16 | Nevro Corporation | Devices for controlling high frequency spinal cord modulation for inhibiting pain, and associated systems and methods, including simplified controllers |
US8868192B2 (en) | 2009-04-22 | 2014-10-21 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US9993645B2 (en) | 2009-04-22 | 2018-06-12 | Nevro Corp. | Devices for controlling high frequency spinal cord modulation for inhibiting pain, and associated systems and methods, including simplified program selection |
US8428748B2 (en) | 2009-04-22 | 2013-04-23 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US9333360B2 (en) | 2009-04-22 | 2016-05-10 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US9333358B2 (en) | 2009-04-22 | 2016-05-10 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US8892209B2 (en) | 2009-04-22 | 2014-11-18 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US8694109B2 (en) | 2009-04-22 | 2014-04-08 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US8694108B2 (en) | 2009-04-22 | 2014-04-08 | Nevro Corporation | Devices for controlling high frequency spinal cord modulation for inhibiting pain, and associated systems and methods, including simplified controllers |
US8554326B2 (en) | 2009-04-22 | 2013-10-08 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US10245433B2 (en) | 2009-04-22 | 2019-04-02 | Nevro Corp. | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US9333357B2 (en) | 2009-04-22 | 2016-05-10 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US10226626B2 (en) | 2009-04-22 | 2019-03-12 | Nevro Corp. | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US11229792B2 (en) | 2009-04-22 | 2022-01-25 | Nevro Corp. | Spinal cord modulation for inducing paresthetic and anesthetic effects, and associated systems and methods |
US11229793B2 (en) | 2009-04-22 | 2022-01-25 | Nevro Corp. | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US8989865B2 (en) | 2009-04-22 | 2015-03-24 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US10220208B2 (en) | 2009-04-22 | 2019-03-05 | Nevro Corp. | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US9333359B2 (en) | 2009-04-22 | 2016-05-10 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US10195433B2 (en) | 2009-04-22 | 2019-02-05 | Nevro Corp. | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US10220209B2 (en) | 2009-04-22 | 2019-03-05 | Nevro Corp. | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
US20120130369A1 (en) * | 2009-05-04 | 2012-05-24 | Ruggero Cadossi | Reversible electroporation device for inducing cell apoptosis |
US11707629B2 (en) | 2009-05-28 | 2023-07-25 | Angiodynamics, Inc. | System and method for synchronizing energy delivery to the cardiac rhythm |
US9895189B2 (en) | 2009-06-19 | 2018-02-20 | Angiodynamics, Inc. | Methods of sterilization and treating infection using irreversible electroporation |
US9610459B2 (en) | 2009-07-24 | 2017-04-04 | Emkinetics, Inc. | Cooling systems and methods for conductive coils |
US20110021863A1 (en) * | 2009-07-24 | 2011-01-27 | Daniel Rogers Burnett | Cooling systems and methods for conductive coils |
US9409019B2 (en) | 2009-07-28 | 2016-08-09 | Nevro Corporation | Linked area parameter adjustment for spinal cord stimulation and associated systems and methods |
US8932289B2 (en) | 2009-10-27 | 2015-01-13 | Holaira, Inc. | Delivery devices with coolable energy emitting assemblies |
US9675412B2 (en) | 2009-10-27 | 2017-06-13 | Holaira, Inc. | Delivery devices with coolable energy emitting assemblies |
US9017324B2 (en) | 2009-10-27 | 2015-04-28 | Holaira, Inc. | Delivery devices with coolable energy emitting assemblies |
US9649153B2 (en) | 2009-10-27 | 2017-05-16 | Holaira, Inc. | Delivery devices with coolable energy emitting assemblies |
US9931162B2 (en) | 2009-10-27 | 2018-04-03 | Nuvaira, Inc. | Delivery devices with coolable energy emitting assemblies |
US8777943B2 (en) | 2009-10-27 | 2014-07-15 | Holaira, Inc. | Delivery devices with coolable energy emitting assemblies |
US9005195B2 (en) | 2009-10-27 | 2015-04-14 | Holaira, Inc. | Delivery devices with coolable energy emitting assemblies |
US20110152855A1 (en) * | 2009-10-27 | 2011-06-23 | Mayse Martin L | Delivery devices with coolable energy emitting assemblies |
US8740895B2 (en) | 2009-10-27 | 2014-06-03 | Holaira, Inc. | Delivery devices with coolable energy emitting assemblies |
US9649154B2 (en) | 2009-11-11 | 2017-05-16 | Holaira, Inc. | Non-invasive and minimally invasive denervation methods and systems for performing the same |
US11712283B2 (en) | 2009-11-11 | 2023-08-01 | Nuvaira, Inc. | Non-invasive and minimally invasive denervation methods and systems for performing the same |
US10610283B2 (en) | 2009-11-11 | 2020-04-07 | Nuvaira, Inc. | Non-invasive and minimally invasive denervation methods and systems for performing the same |
US8911439B2 (en) | 2009-11-11 | 2014-12-16 | Holaira, Inc. | Non-invasive and minimally invasive denervation methods and systems for performing the same |
US11389233B2 (en) | 2009-11-11 | 2022-07-19 | Nuvaira, Inc. | Systems, apparatuses, and methods for treating tissue and controlling stenosis |
US9149328B2 (en) | 2009-11-11 | 2015-10-06 | Holaira, Inc. | Systems, apparatuses, and methods for treating tissue and controlling stenosis |
US20110118725A1 (en) * | 2009-11-11 | 2011-05-19 | Mayse Martin L | Non-invasive and minimally invasive denervation methods and systems for performing the same |
US10631912B2 (en) | 2010-04-30 | 2020-04-28 | Medtronic Xomed, Inc. | Interface module for use with nerve monitoring and electrosurgery |
US11950832B2 (en) | 2010-04-30 | 2024-04-09 | Medtronic Xomed, Inc. | Interface module for use with nerve monitoring and electrosurgery |
US10980593B2 (en) | 2010-04-30 | 2021-04-20 | Medtronic Xomed, Inc. | Interface module for use with nerve monitoring and electrosurgery |
US8588884B2 (en) | 2010-05-28 | 2013-11-19 | Emkinetics, Inc. | Microneedle electrode |
US11931096B2 (en) | 2010-10-13 | 2024-03-19 | Angiodynamics, Inc. | System and method for electrically ablating tissue of a patient |
US10857361B2 (en) | 2010-11-11 | 2020-12-08 | Spr Therapeutics, Inc. | Systems and methods for the treatment of pain through neural fiber stimulation |
US10722715B2 (en) | 2010-11-11 | 2020-07-28 | Spr Therapeutics, Inc. | Systems and methods for the treatment of pain through neural fiber stimulation |
US10076663B2 (en) | 2010-11-11 | 2018-09-18 | Spr Therapeutics, Inc. | Systems and methods for the treatment of pain through neural fiber stimulation |
US11612746B2 (en) | 2010-11-11 | 2023-03-28 | Spr Therapeutics, Inc. | Systems and methods for the treatment of pain through neural fiber stimulation |
US9707394B2 (en) | 2010-11-11 | 2017-07-18 | Spr Therapeutics, Llc | Systems and methods for the treatment of pain through neural fiber stimulation generating a stochastic response |
US11344726B2 (en) | 2010-11-11 | 2022-05-31 | Spr Therapeutics, Inc. | Systems and methods for the treatment of pain through neural fiber stimulation |
US9180298B2 (en) | 2010-11-30 | 2015-11-10 | Nevro Corp. | Extended pain relief via high frequency spinal cord modulation, and associated systems and methods |
US8649874B2 (en) | 2010-11-30 | 2014-02-11 | Nevro Corporation | Extended pain relief via high frequency spinal cord modulation, and associated systems and methods |
US10258796B2 (en) | 2010-11-30 | 2019-04-16 | Nevro Corp. | Extended pain relief via high frequency spinal cord modulation, and associated systems and methods |
US20120310140A1 (en) * | 2010-12-01 | 2012-12-06 | Spinal Modulation, Inc. | Directed delivery of agents to neural anatomy |
US9789313B2 (en) | 2011-02-23 | 2017-10-17 | John D. LIPANI | System and methods for diagnosis and treatment of discogenic lower back pain |
US8892215B2 (en) | 2011-02-23 | 2014-11-18 | John D. LIPANI | System and method for electrical stimulation of the lumbar vertebral column |
US8880189B2 (en) | 2011-02-23 | 2014-11-04 | John D. LIPANI | System and method for electrical stimulation of the lumbar vertebral column |
US9630011B2 (en) | 2011-02-23 | 2017-04-25 | John D Lipani | System and methods for diagnosis and treatment of discogenic lower back pain |
US9950164B2 (en) | 2011-02-23 | 2018-04-24 | John D Lipani | System and methods for diagnosis and treatment of discogenic lower back pain |
US10702326B2 (en) | 2011-07-15 | 2020-07-07 | Virginia Tech Intellectual Properties, Inc. | Device and method for electroporation based treatment of stenosis of a tubular body part |
US9662063B2 (en) | 2011-08-25 | 2017-05-30 | Inter-University Research Institute Corporation National Institutes Of Natural Sciences | Pain sensory nerve stimulation apparatus |
EP2561906A1 (en) * | 2011-08-25 | 2013-02-27 | Nihon Kohden Corporation | Pain sensory nerve stimulation apparatus |
US9283388B2 (en) | 2011-09-08 | 2016-03-15 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods |
US10493277B2 (en) | 2011-09-08 | 2019-12-03 | Nevro Corp. | Selective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods |
US9278215B2 (en) | 2011-09-08 | 2016-03-08 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods |
US9283387B2 (en) | 2011-09-08 | 2016-03-15 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods |
US11883663B2 (en) | 2011-09-08 | 2024-01-30 | Nevro Corp. | Selective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods |
US11298539B2 (en) | 2011-09-08 | 2022-04-12 | Nevro Corp. | Selective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods |
US9295839B2 (en) | 2011-09-08 | 2016-03-29 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods |
US9327121B2 (en) | 2011-09-08 | 2016-05-03 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods |
US9757196B2 (en) | 2011-09-28 | 2017-09-12 | Angiodynamics, Inc. | Multiple treatment zone ablation probe |
US11779395B2 (en) | 2011-09-28 | 2023-10-10 | Angiodynamics, Inc. | Multiple treatment zone ablation probe |
US11471210B2 (en) | 2011-12-30 | 2022-10-18 | Relievant Medsystems, Inc. | Methods of denervating vertebral body using external energy source |
US9002460B2 (en) | 2012-04-02 | 2015-04-07 | Nevro Corporation | Devices for controlling spinal cord modulation for inhibiting pain, and associated systems and methods, including controllers for automated parameter selection |
US8676331B2 (en) | 2012-04-02 | 2014-03-18 | Nevro Corporation | Devices for controlling spinal cord modulation for inhibiting pain, and associated systems and methods, including controllers for automated parameter selection |
US9604059B2 (en) | 2012-04-02 | 2017-03-28 | Nevro Corp. | Devices for controlling spinal cord modulation for inhibiting pain, and associated systems and methods, including controllers for automated parameter selection |
US11103700B2 (en) | 2012-04-25 | 2021-08-31 | Medtronic, Inc. | Stimulation probe for robotic and laparoscopic surgery |
WO2013177006A3 (en) * | 2012-05-21 | 2015-06-18 | Stimwave Technologies, Incorporated | Methods and devices for modulating excitable tissue of the exiting spinal nerves |
US10328256B1 (en) | 2012-06-22 | 2019-06-25 | Nevro Corp. | Autonomic nervous system control via high frequency spinal cord modulation, and associated systems and methods |
US9833614B1 (en) | 2012-06-22 | 2017-12-05 | Nevro Corp. | Autonomic nervous system control via high frequency spinal cord modulation, and associated systems and methods |
US11247057B1 (en) | 2012-06-22 | 2022-02-15 | Nevro Corp. | Autonomic nervous system control via high frequency spinal cord modulation, and associated systems and methods |
US20200281646A1 (en) * | 2012-09-12 | 2020-09-10 | Relievant Medsystems, Inc. | Radiofrequency ablation of tissue within a vertebral body |
US11737814B2 (en) * | 2012-09-12 | 2023-08-29 | Relievant Medsystems, Inc. | Cryotherapy treatment for back pain |
US11701168B2 (en) | 2012-09-12 | 2023-07-18 | Relievant Medsystems, Inc. | Radiofrequency ablation of tissue within a vertebral body |
US11690667B2 (en) | 2012-09-12 | 2023-07-04 | Relievant Medsystems, Inc. | Radiofrequency ablation of tissue within a vertebral body |
US10004557B2 (en) | 2012-11-05 | 2018-06-26 | Pythagoras Medical Ltd. | Controlled tissue ablation |
US9770593B2 (en) | 2012-11-05 | 2017-09-26 | Pythagoras Medical Ltd. | Patient selection using a transluminally-applied electric current |
ITMO20120275A1 (en) * | 2012-11-13 | 2014-05-14 | Claudio Reverberi | PERCUTANEOUS ELECTRODE FOR MIDOLLAR NEUROSTIMULATION. |
US9398933B2 (en) | 2012-12-27 | 2016-07-26 | Holaira, Inc. | Methods for improving drug efficacy including a combination of drug administration and nerve modulation |
US9888956B2 (en) | 2013-01-22 | 2018-02-13 | Angiodynamics, Inc. | Integrated pump and generator device and method of use |
US9724535B1 (en) * | 2013-02-19 | 2017-08-08 | Blugreen Technologies, Inc. | Low frequency magnetic pulse variable resonator for actively influencing the interaction and intercommunication at the cellular level for biological organisms and molecular level of matter |
US10918853B2 (en) | 2013-05-30 | 2021-02-16 | Neurostim Solutions, Llc | Topical neurological stimulation |
US11291828B2 (en) | 2013-05-30 | 2022-04-05 | Neurostim Solutions LLC | Topical neurological stimulation |
US10307591B2 (en) | 2013-05-30 | 2019-06-04 | Neurostim Solutions, Llc | Topical neurological stimulation |
US10016600B2 (en) | 2013-05-30 | 2018-07-10 | Neurostim Solutions, Llc | Topical neurological stimulation |
US10946185B2 (en) | 2013-05-30 | 2021-03-16 | Neurostim Solutions, Llc | Topical neurological stimulation |
US11229789B2 (en) | 2013-05-30 | 2022-01-25 | Neurostim Oab, Inc. | Neuro activator with controller |
US10751536B1 (en) | 2013-06-10 | 2020-08-25 | Nevro Corp. | Methods and systems for disease treatment using electrical stimulation |
US9895539B1 (en) | 2013-06-10 | 2018-02-20 | Nevro Corp. | Methods and systems for disease treatment using electrical stimulation |
US11957405B2 (en) | 2013-06-13 | 2024-04-16 | Angiodynamics, Inc. | Methods of sterilization and treating infection using irreversible electroporation |
US20170056653A1 (en) * | 2013-10-09 | 2017-03-02 | GiMer Medical Co., Ltd. | Method for reducing overactive bladder syndrome and computer-readable medium thereof |
US10632310B2 (en) | 2013-10-09 | 2020-04-28 | GiMer Medical Co., Ltd. | Electronic stimulation device, method of treatment and electronic stimulation system |
US10086197B2 (en) * | 2013-10-09 | 2018-10-02 | GiMer Medical Co., Ltd. | Method for reducing overactive bladder syndrome and computer-readable medium thereof |
US9956408B2 (en) | 2013-10-09 | 2018-05-01 | Gimer Medical Co. Ltd. | Method for reducing spasticity and non-transitory computer-readable medium thereof |
US10086201B2 (en) * | 2013-10-09 | 2018-10-02 | GiMer Medical Co., Ltd. | Electronic stimulation device, method of treatment and electronic stimulation system |
US10639476B2 (en) | 2013-10-09 | 2020-05-05 | GiMer Medical Co., Ltd. | Electronic stimulation device, method of treatment and electronic stimulation system |
US20160045735A1 (en) * | 2013-10-09 | 2016-02-18 | GiMer Medical Co., Ltd. | Electronic stimulation device, method of treatment and electronic stimulation system |
US10183165B2 (en) | 2013-10-09 | 2019-01-22 | GiMer Medical Co., Ltd. | Method of reducing renal hypertension and computer-readable medium |
US10576286B1 (en) | 2013-11-07 | 2020-03-03 | Nevro Corp. | Spinal cord modulation for inhibiting pain via short pulse width waveforms, and associated systems and methods |
US10569089B1 (en) | 2013-11-07 | 2020-02-25 | Nevro Corp. | Spinal cord modulation for inhibiting pain via short pulse width waveforms, and associated systems and methods |
US10149978B1 (en) | 2013-11-07 | 2018-12-11 | Nevro Corp. | Spinal cord modulation for inhibiting pain via short pulse width waveforms, and associated systems and methods |
US10556112B1 (en) | 2013-11-07 | 2020-02-11 | Nevro Corp. | Spinal cord modulation for inhibiting pain via short pulse width waveforms, and associated systems and methods |
US10478249B2 (en) | 2014-05-07 | 2019-11-19 | Pythagoras Medical Ltd. | Controlled tissue ablation techniques |
US10471254B2 (en) | 2014-05-12 | 2019-11-12 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
US11406820B2 (en) | 2014-05-12 | 2022-08-09 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
US20160074626A1 (en) * | 2014-09-15 | 2016-03-17 | Ethicon, Inc. | System and Method for Targeted Delivery of Therapeutic Agents to Tissue |
US10376674B2 (en) * | 2014-09-15 | 2019-08-13 | Ethicon, Inc. | System and method for targeted delivery of therapeutic agents to tissue |
US9764137B2 (en) * | 2014-10-01 | 2017-09-19 | GiMer Medical Co., Ltd. | Electronic stimulation system and device thereof for dorsal root ganglion |
US20160096022A1 (en) * | 2014-10-01 | 2016-04-07 | GiMer Medical Co., Ltd. | Electronic stimulation system and device thereof for dorsal root ganglion |
US20160096021A1 (en) * | 2014-10-01 | 2016-04-07 | GiMer Medical Co., Ltd. | Electronic stimulation system and device thereof for dorsal root ganglion |
US9770592B2 (en) * | 2014-10-01 | 2017-09-26 | GiMer Medical Co., Ltd. | Electronic stimulation system and device thereof for dorsal root ganglion |
US10694972B2 (en) | 2014-12-15 | 2020-06-30 | Virginia Tech Intellectual Properties, Inc. | Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment |
US11903690B2 (en) | 2014-12-15 | 2024-02-20 | Virginia Tech Intellectual Properties, Inc. | Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment |
US11077301B2 (en) | 2015-02-21 | 2021-08-03 | NeurostimOAB, Inc. | Topical nerve stimulator and sensor for bladder control |
US10383685B2 (en) | 2015-05-07 | 2019-08-20 | Pythagoras Medical Ltd. | Techniques for use with nerve tissue |
US11318310B1 (en) | 2015-10-26 | 2022-05-03 | Nevro Corp. | Neuromodulation for altering autonomic functions, and associated systems and methods |
US11596798B2 (en) | 2016-01-25 | 2023-03-07 | Nevro Corp | Treatment of congestive heart failure with electrical stimulation, and associated systems and methods |
US10799701B2 (en) | 2016-03-30 | 2020-10-13 | Nevro Corp. | Systems and methods for identifying and treating patients with high-frequency electrical signals |
US11678932B2 (en) | 2016-05-18 | 2023-06-20 | Symap Medical (Suzhou) Limited | Electrode catheter with incremental advancement |
US11446504B1 (en) | 2016-05-27 | 2022-09-20 | Nevro Corp. | High frequency electromagnetic stimulation for modulating cells, including spontaneously active and quiescent cells, and associated systems and methods |
US11541235B2 (en) | 2016-08-26 | 2023-01-03 | Spr Therapeutics, Inc. | Devices and methods for delivery of electrical current for pain relief |
US11806300B2 (en) | 2016-10-21 | 2023-11-07 | Spr Therapeutics, Inc. | Method and system of mechanical nerve stimulation for pain relief |
US11540973B2 (en) | 2016-10-21 | 2023-01-03 | Spr Therapeutics, Llc | Method and system of mechanical nerve stimulation for pain relief |
CN111135461A (en) * | 2016-11-04 | 2020-05-12 | 精能医学股份有限公司 | Electrical stimulation device, signal generation method and non-transitory computer readable storage medium |
CN108014419A (en) * | 2016-11-04 | 2018-05-11 | 精能医学股份有限公司 | Electrical stimulation device and signal generating method, non-transient computer-readable storage media |
AU2019204642B2 (en) * | 2016-11-04 | 2020-07-02 | Gimer Medical. Co. Ltd. | Method for reducing overactive bladder syndrome and computer-readable medium thereof |
US11723710B2 (en) | 2016-11-17 | 2023-08-15 | Angiodynamics, Inc. | Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode |
US10953225B2 (en) | 2017-11-07 | 2021-03-23 | Neurostim Oab, Inc. | Non-invasive nerve activator with adaptive circuit |
US11607537B2 (en) | 2017-12-05 | 2023-03-21 | Virginia Tech Intellectual Properties, Inc. | Method for treating neurological disorders, including tumors, with electroporation |
US11938317B2 (en) | 2017-12-26 | 2024-03-26 | Galvanize Therapeutics, Inc. | Optimization of energy delivery for various applications |
US11925405B2 (en) | 2018-03-13 | 2024-03-12 | Virginia Tech Intellectual Properties, Inc. | Treatment planning system for immunotherapy enhancement via non-thermal ablation |
US11311329B2 (en) | 2018-03-13 | 2022-04-26 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for immunotherapy based treatments using non-thermal ablation techniques |
US20210290172A1 (en) * | 2018-05-07 | 2021-09-23 | Farapulse, Inc. | Systems, apparatuses, and methods for filtering high voltage noise induced by pulsed electric field ablation |
US11602634B2 (en) | 2019-01-17 | 2023-03-14 | Nevro Corp. | Sensory threshold adaptation for neurological therapy screening and/or electrode selection, and associated systems and methods |
US11590352B2 (en) | 2019-01-29 | 2023-02-28 | Nevro Corp. | Ramped therapeutic signals for modulating inhibitory interneurons, and associated systems and methods |
US20210244951A1 (en) * | 2019-03-08 | 2021-08-12 | Mayo Foundation For Medical Education And Research | Systems and methods for stellate ganglion stimulation and ablation |
EP3927421A4 (en) * | 2019-03-08 | 2022-11-23 | Mayo Foundation for Medical Education and Research | Systems and methods for stellate ganglion stimulation and ablation |
CN114007535A (en) * | 2019-04-18 | 2022-02-01 | 盖乐世公司 | Devices, systems, and methods for treating abnormal tissue |
US11458311B2 (en) | 2019-06-26 | 2022-10-04 | Neurostim Technologies Llc | Non-invasive nerve activator patch with adaptive circuit |
US11950835B2 (en) | 2019-06-28 | 2024-04-09 | Virginia Tech Intellectual Properties, Inc. | Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy |
US11730958B2 (en) | 2019-12-16 | 2023-08-22 | Neurostim Solutions, Llc | Non-invasive nerve activator with boosted charge delivery |
Also Published As
Publication number | Publication date |
---|---|
US20100010567A1 (en) | 2010-01-14 |
US9345538B2 (en) | 2016-05-24 |
US8504147B2 (en) | 2013-08-06 |
US8989859B2 (en) | 2015-03-24 |
US20140200573A1 (en) | 2014-07-17 |
US20140012256A1 (en) | 2014-01-09 |
US8676309B2 (en) | 2014-03-18 |
US20150216588A1 (en) | 2015-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9345538B2 (en) | Systems and methods for neuromodulation for treatment of disorders associated with nerve conduction | |
AU2020204495B2 (en) | Device and methods for delivery of stimulation to a body tissue | |
US10994131B2 (en) | Method to treat pain through electrical stimulation of nerves | |
US10130792B2 (en) | Methods for therapeutic renal neuromodulation using neuromodulatory agents or drugs | |
JP7176949B2 (en) | Nerve conduction modification system and method by percutaneous direct current block | |
ES2355462T3 (en) | SYSTEM FOR THE MODIFICATION OF NERVOUS TISSUE. | |
US8027718B2 (en) | Regional anesthetic | |
US9220895B2 (en) | Noninvasive or percutaneous nerve stimulation | |
US20100016929A1 (en) | Method and system for controlled nerve ablation | |
US20140288545A1 (en) | Methods for Bilateral Renal Neuromodulation | |
US20050261672A1 (en) | Systems and methods for selective denervation of heart dysrhythmias | |
WO2001010375A2 (en) | Inhibition of action potentials | |
US20120290059A1 (en) | System and method for electrical modulation of the posterior longitudinal ligament | |
Triantis | 8 NERVE STIMULATION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THE FOUNDRY, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DEEM, MARK E.;GIFFORD, HANSON;REEL/FRAME:018275/0239 Effective date: 20060821 |
|
AS | Assignment |
Owner name: THE FOUNDRY, LLC, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THE FOUNDRY, INC.;REEL/FRAME:022520/0499 Effective date: 20090402 Owner name: THE FOUNDRY, LLC,CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THE FOUNDRY, INC.;REEL/FRAME:022520/0499 Effective date: 20090402 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: ARDIAN, INC.,CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THE FOUNDRY, LLC;REEL/FRAME:024289/0742 Effective date: 20091104 Owner name: ARDIAN, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THE FOUNDRY, LLC;REEL/FRAME:024289/0742 Effective date: 20091104 |